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1. INTRODUCTION  
 1.1. Transdermal Drug Delivery Systems 1, 2 
Currently, transdermal drug  delivery is one of the most promising 
methods for drug application. Increasing numbers of drugs are being added to the 
list of therapeutic agents that can be delivered to the systemic circulation via skin. 
Transdermal drug delivery systems (TDDS) can be defined as self contained 
discrete dosage forms which, when applied to the intact skin, delivers the drug(s) 
through the skin at a controlled rate to the systemic circulation. 
The potential of using intact skin as the route of drug administration has 
been known for several years. The inspiration of using skin for delivery of drug is 
from ancient time. Ebers papyrus used the husk of castor oil plant bark imbibed 
with water placed on aching head. Historically, the medicated plaster can be 
viewed as the first development of transdermal drug delivery; this medicated 
plaster became very popular in Japan as over the counter pharmaceutical dosage 
form 
Transdermal delivery not only provides controlled, constant administration 
of the drug, but also allows continuous input of drugs with short biological half-
life  and eliminates pulsed entry into systemic circulation, which often undesirable 
side effect. 
TDDS facilitate the passage of therapeutic quantities of drug substances 
through the skin and into the general circulation for their systemic effects.  
 In developing a transdermal delivery system, two criteria are considered: 
one is achieving adequate flux across the skin and the other is minimizing the lag 
time in skin permeation. One strategy overcoming this constraint is the 
incorporation of various chemical skin enhancers into the vehicle. Another 
strategy is a choice of an appropriate vehicle that corresponds to the drug being 
used for the dermal route of administration.  
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Concerning dermal application the microemulsions can interact with the 
stratum corneum changing structural rearrangement of its lipid layers and 
consequently increasing transdermal drug permeation and so act as penetration 
enhancer  
1.1.1. Advantages of TDDS3 
 Avoidance of first pass metabolism 
 Avoidance of gastro intestinal incompatibility  
 Predictable and extended duration of activity 
 Minimizing undesirable side effects 
 Provides utilization of drugs with short biological half life 
 Narrow therapeutic window 
 Improving physiological and pharmacological response 
 Avoidance the fluctuation in drug levels 
 Termination of therapy is easy at any point of time 
 Greater patient compliance due to elimination of multiple dosing profile 
 Ability to deliver drug more selectively to a specific site 
 Provide suitability for self administration 
 Enhance therapeutic efficacy  
1.1.2. Limitations of TDDS  
¾ Transdermal route administration is unsuitable for drugs that irritate or 
sensitize the skin 
¾ Transdermal route  cannot deliver in a pulsatile fashion 
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¾ Transdermal delivery is neither practical nor affordable when required to 
deliver large doses of drugs through skin 
¾ Transdermal delivery cannot administer drugs that require high blood 
levels 
¾ Drug of drug formulation may cause irritation or sensitization 
¾ Not practical, when the drug is extensively metabolized in the skin and 
when molecular size is great enough to prevent the molecules from 
diffusing through the skin 
¾ Not suitable for a drug, which doesn’t possess a favourable, O/W partition 
coefficient 
¾ The barrier functions of the skin of changes from one site to another on the 
same person, from person to person and with age 
1.1.3. The Human Skin4  
One highly successful alternative delivery method is the transdermal. Skin 
of an average adult body covers a surface of approximately 2m2 and receives 
about one-third of the blood circulating through the body. The deliver a drug into 
the body through transdermal layer of skin, it is necessary to understand about the 
skin. 
 The skin is the outer covering of the body. In humans, it is the largest 
organ of the integumentary system made up of multiple layers of epithelial tissues 
and guards the underlying muscles, bones, ligaments and internal organs. For the 
average adult human, the skin has a surface area between 1.5 to 2 m2 (16.1-21.5 sq 
ft), most of it is between 2.3mm (0.10 inch) thick. The average square inch 
(6.5cm2) of skin holds 650 sweat glands, 20 blood vessels, 60,000 melanocytes 
and more than a thousand nerve endings. It performs several essential functions. 
The adjective cutaneous literally means “of the skin” (from Latin cutis, skin).The 
different layers of the human skin is shown in fig 1. 
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Fig 1: Anatomy of the Skin 
 
1.1.4. Anatomy of the Skin 
Structurally, the skin consists of two principle parts. The outer thinner 
portion, which is composed of epithelium, is called the epidermis. The epidermis 
is attached to the inner thicker, connective tissue part called the dermis. Beneath 
the dermis is a subcutaneous layer. This layer is also called the superficial fascia 
or hypodermis. It consists of areole and adipose tissues. Fibers from the dermis 
extend down into the subcutaneous layer and anchor the skin to it. The 
subcutaneous layer in turn attaches to underlying tissues and organs.  
Skin layers: 
 
Skin is composed of three primary layers. 
♣ Epidermis 
♣ Dermis 
♣ Hypodermis (subcutaneous adipose layer). 
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Epidermis:  
Epidermis, “epi’ coming from the Greek meaning “over” or “upon” is the 
outermost layer of the skin. It forms the water proof, protective wrap over the 
body’s surface and is made up of stratified squamous epithelium with an 
underlying basal lamina. It contains no blood vessels and cells in the deepest layer 
are nourished by diffusion from blood capillaries extending to the upper layers of 
the dermis.  
Dermis: 
Dermis is 3 to 5mm thick layer and is composed of a matrix of connective 
tissue, which contains blood vessels, lymph vessels and nerves. The cutaneous 
blood supply has essential function in regulation of body temperature. It also 
provides nutrients and oxygen to the skin while removing toxins and waste 
products.  
Capillaries reach to within 0.2 mm of skin surface and provide sink 
conditions for most molecules penetrating the skin barrier. The blood supply thus 
keeps the dermal concentration of a permeant very low and the resulting 
concentration difference across the epidermis provides the essential concentration 
gradient for transdermal permeation. It contains hair follicles, sweat gland, 
sebaceous glands, apocrine glands, lymphatic vessels and blood vessels. 
Hypodermis:  
The hypodermis or subcutaneous fat tissue supports the dermis and 
epidermis. It serves as a fat storage area. This layer helps to regulate temperature, 
provides nutritional support and mechanical protection. It carries principle blood 
vessels and nerves to skin and may contain sensory pressure organs. For 
transdermal drug delivery, drug has to penetrate through all these three layers and 
reach into systemic circulation while in case of topical drug delivery only 
penetration through stratum corneum is essential and then retention of drug in skin 
layers is desired. It consists of loose connective tissue and elastic. The main cell 
types are fibroblasts, macrophages and adipocytes. 
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1.1.5. Drug Delivery Routes Across  Human Skin6,7  
Drug molecules in contact with the  skin surface can penetrate by three 
potential potential pathways: through the sweat ducts, via the hair follicles and 
sebaceous glands, (collectively called the shunt or appendageal route), or directly  
across the stratum corneum(Fig 2). 
The relative importance of the shunt or appendageal route versus transport 
across the stratum corneum has been debated by scientists over the years(6-8) and 
is further complicated by the lack of a suitable experimental model to permit 
separation of the three pathways. 
In vivo experiments tend to involve the use of hydrated skin or epidermal 
membranes so that appendages are closed by the swelling associated with 
hydration. Scheuplein and colleagues proposed that a follicular shunt route was 
responsible for the presteady-State permeation of polar molecules and flux of 
large polar molecules or ions that have difficulty diffusing across the intact 
stratum corneum. 
 
 
 
 
 
 
Fig 2: Routes of penetration 
 1. Through the sweat ducts; 2. Directly across the stratum corneum; 
3.Via the hair follicles. 
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The stratum corneum consists of 10-15 layers of corneocytes and varies in 
thickness from approximately 10-15µm in the dry state to 40µm when hydrated. It 
comprises a multi-layered “brick and mortar” like structure of keratin-rich 
corneocytes (bricks) in an intercellular matrix (mortar) composed primarily of 
long chain ceramides, free fatty acids, triglycerides, cholesterol, cholesterol 
sulfate and sterol/wax esters. However it is important to view this model in the 
context that the corneocytes are not brick shaped but are polygonal, elongated and 
flat (0.2-1.5µm thick, 34-46 µm in diameter). 
The intercellular lipid matrix is generated by keratinocytes in the mid to 
upper part of the stratum granulosum discharging their lamellar contents into the 
intercellular space. In the initial layers of the stratum this extruded material 
rearranges to form broad intercellular lipid lamellae, which then associate into 
lipid bilayers, with the hydrocarbon chains aligned and polar head groups 
dissolved in an aqueous layer Fig 3. 
As a result of the stratum corneum lipid composition, the lipid phase 
behaviour is different from that of other biological membranes.the hydrocarbon 
chains are arranged into regions of crystalline,lamellar gel and lamellar liquid 
crystal phases thereby creating various domains within the lipid bilayers.The 
presence of intrinsic and extrinsic proteins,such as enzymes,may also affect the 
lamellar structure of the stratum corneum. 
Water is an essential component of the stratum corneum,which acts as a 
plasticizer to prevent cracking of the stratum corneum and is also involved in the 
generation of natural moisturizing factor(NMF), which helps to maintain 
suppleness. In order to understand how the physicochemical propreties of the 
diffusing drug and vehicle influence permeation across the stratum corneum and 
thereby optimise delivery, it is essential to determine the predominant route of 
drug   permeation with in the stratum corneum.  
Traditionally it was thought that hydrophilic chemicals diffuse within the 
aqueous regions near the outer surface of intracellular keratin filaments 
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(intracellular or transcellular route) while lipophilic chemicals diffuse through the 
lipid matrix between the filaments (intracellular route) 
 
Fig 3: The stratum corneum and intercellular and transcellular 
routes of penetration 
1.1.7 Factors Affecting Transdermal Permeation7, 8 
Physicochemical factors: 
A. Biological factors 
i) Skin condition  
 Acids and alkalis, many solvents like chloroform, methanol damage the 
skin cells and promote penetration. Diseased state of patient alters the skin 
conditions. The intact skin is better barrier but the above mentioned conditions 
affect penetration. 
ii) Skin age 
 The young skin is more permeable than older. Childrens are more sensitive 
for skin absorption of toxins. Thus, skin age is one of the factor affecting 
penetration of drug in TDDS. 
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iii) Blood supply 
  Changes in peripheral circulation can affect transdermal absorption. 
iv) Regional skin site 
  Thickness of skin, nature of stratum corneum and density of appendages 
vary site to site. These factors affect significantly penetration. 
 
v) Skin metabolism 
 Skin metabolizes steroids, hormones, chemical carcinogens and some 
drugs. So skin metabolism determines efficacy of drug permeated through the 
skin.  
vi) Species differences 
 The skin thickness, density of appendages and keratinization of skin vary 
species to species, so affects the penetration.  
B. Physicochemical factors 
i) Skin hydration 
 In contact with water the permeability of skin increases significantly. 
Hydration is most important factor increasing the permeation of skin. So use of 
humectant is done in transdermal delivery. 
ii) Temperature and pH 
  The permeation of drug increases, ten folds with temperature variation. 
The diffusion coefficient decreases as temperature falls. Weak acids and weak 
bases dissociate depending on the pH and pka or pkb values. The proportion of 
unionized drug determines the drug concentration in skin. Thus, temperature and 
pH are important factors affecting drug penetration.  
iii) Diffusion coefficient 
  Penetration of drug depends on diffusion coefficient of drug. At a constant 
temperature the diffusion coefficient of drug depends on properties of drug, 
diffusion medium and interaction between them.  
iv) Drug concentration 
 The flux is proportional to the concentration gradient across the barrier and 
concentration gradient will be higher if the concentration of drug will be more 
across the barrier.  
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v) Partition coefficient 
 The optimal partition coefficient (K) is required for good action. Drugs 
with high K are not ready to leave the lipid portion of skin. Also, drugs with low 
K will not be permeated. 
 
vi) Molecular size and shape 
 Drug absorption is inversely related to molecular weight, small molecules 
penetrate faster than large ones. Ideal molecular properties for transdermal drug 
delivery. 
1.2. Microemulsion9, 10 
In 1943, Hour and Schulman visualized the existence of small emulsion-
like structures by electron microscopy and subsequently coined the term 
“microemulsions”. Microemulsions are isotropic, thermodynamically stable 
transparent (or translucent) systems of oil, water and surfactant, frequently in 
combination with a co-surfactant with a droplet size usually in the range of 10-100 
nm. where as the diameter of droplets in a kinetically stable emulsion is >500 nm. 
Because the droplets are small, a microemulsion offers advantages as a carrier for 
drugs that are poorly soluble in water. These homogeneous systems, which can be 
prepared over a wide range of surfactant concentration and oil to water ratio, are 
all fluids of low viscosity. 
 
Fig 4: Microemulsion 
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1.2.1. Important Characteristics of Microemulsions11, 12 
 
• Particle size 10-100 nm 
• Thermodynamically stable (long shelf-life) 
• Optically clear 
• High surface area (high solubilization capacity) 
• Small droplet size 
• Enhanced drug solubilization 
• Ease formation (zero interfacial tension and almost spontaneous 
formation) 
• Ability to be sterilized by filtration 
 
• Long-term stability 
 
• High solubilization capacity for hydrophilic and lipophilic drugs 
• Improved drug delivery  
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Table 1: Difference between Emulsion and Microemulsion 
EMULSION MICROEMULSION 
EMULSION MICROEMULSION 
Emulsions consist of roughly spherical 
droplets of one phase dispersed into the 
other. 
They constantly evolve between various 
structures ranging from droplet like swollen 
micelles to bi-continuous structure 
Thermodynamically unstable 
     (Kinetically Stable) 
Thermodynamically stable 
       (Long shelf-life) 
Inefficient molecular packing Efficient molecular packing 
Direct oil/water contact at the interface No direct oil/water contact at the interface 
High interfacial tension Ultra low interfacial tension 
High viscosity Low viscosity with Newtonian behavior 
Droplet diameter: >500nm 10 – 100 nm 
Cloudy colloidal system Optically transparent(Isotropic) 
 
They are lyophobic 
They are on the borderline between 
lyophobic and lyophilic colloids 
 
Require intense agitation for their formation 
Generally obtained by gentle mixing of 
ingredients. 
Ordinary emulsion droplets, however small 
exist as individual entities until coalesance 
or ostwald ripening occurs 
Microemulsion droplet may disappear 
within a fraction of a second while another 
droplet forms spontaneously elsewhere in 
the system 
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Fig 5: Difference between Emulsion and Microemulsion 
1.2.2. Microemulsion as Drug Delivery Systems13 
1.2.3. Oral drug delivery 
The most common method for drug delivery is through the oral route as it 
offers convenience and high patient compliance. 
1.2.4. Parenteral drug delivery 
Microemulsion systems intended for parenteral application have to be 
formulated using nontoxic and biocompatible ingredients. The oil in water 
microemulsion systems would be suitable to improve the solubility of poorly 
water soluble drug molecules whereas water in oil microemulsion systems would 
be best suited for optimizing the delivery of hydrophilic drug molecules that are 
susceptible to the harsh gastrointestinal condition 
1.2.5. Ocular drug delivery  
Aqueous solutions account for around 90% of the available ophthalmic 
formulations, mainly due to their simplicity and convenience However, extensive 
loss caused by rapid precorneal drainage and high tear turnover are among the 
main drawbacks associated with topical ocular drug delivery. 
1.2.6. Topical drug delivery 
1.2.7. Transdermal Drug Delivery 
To the systemic circulation is one of the oldest routes that have been 
exploited using microemulsion systems.  
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1.2.8. Advantages of Microemulsion14 
¾ Thermodynamically stable and require minimum energy for formation 
¾ To increase the cutaneous absorption of both lipophilic and hydrophilic 
drugs when compared to conventional vehicles (emulsions, pure oils, 
aqueous solutions). 
¾ Ease of preparation and high diffusion and absorption rates when 
compared to solvent without the surfactant system 
¾ The formation of microemulsion is reversible. They may become unstable 
at low or high temperature but when the temperature to the stability range, 
the microemulsion reforms 
¾ Drugs that are thermo-labile are easily incorporated without the risk of 
degradation  
¾ Microemulsions act as supersolvent of drug. They can solubilize 
hydrophilic and lipophilic drugs including drugs that are relatively 
insoluble in both aqueous and hydrophobic solvents. 
¾ This system is reckoned advantages because of its wide applications in 
colloidal drug delivery systems for the purpose of drug targeting and 
controlled release. 
¾ A large amount of drug can be incorporated in the formulation due to the 
high solubilizing capacity that might increase thermodynamic activity 
towards the skin  
¾ The surfactant and co surfactant in the microemulsions may reduce the 
diffusional barrier of the stratum corneum by acting as penetration 
enhancers  
¾ Low surface tension ensures good contact to the skin. Also, the dispersed 
phase can act as a reservoir making it possible to maintain an almost 
constant concentration gradient over the skin for a long time 
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1.2.9. Disadvantages of Microemulsion 
¾ Use of large concentration of surfactant and co-surfactant necessary for 
stabilizing the nanodroplets. 
¾ Limited solubilizing capacity for high-melting substances 
¾ The surfactant must be nontoxic for using pharmaceutical applications 
¾ Microemulsion stability is influenced environmental parameters such 
as temperature and pH. These parameters change upon microemulsion 
delivery to patients 
1.2.10. Techniques Used to Characterize Microemulsions and Related 
             Systems15 
The physicochemical and analytical techniques used to characterize 
microemulsion and related systems could be categorized into those used to: 
¾ Elucidate the microstructure and monitor phase behavior changes 
¾ Determine the droplet size of the disperse phase  
The choice of a particular technique is limited by factors such as 
availability, feasibility, and the nature of the information sought. Pharmaceutical 
scientists are more focused on the usefulness of a particular microemulsion system 
for a drug delivery application and the influence of the microstructure on that, 
rather than on the fundamental understanding of aspects such as microstructure 
and phase behavior. 
 
1.2.11. Structure of Microemulsions16 
The mixture of oil, water and surfactants is able to form a wide variety of 
structures and phases depending upon the proportions of the components. The 
flexibility of the surfactant film is an important factor in this regard. A flexible 
surfactant film will enable the existence of several different structures like droplet 
like shapes, aggregates and bicontinuous structures, and therefore broaden the 
range of microemulsion existence.  
 
A very rigid surfactant film will not enable existence of bicontinuous 
structures which will impede the range of existence. Besides microemulsions, 
structural examinations can reveal the existence of regular emulsions, anisotropic 
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crystalline hexagonal or cubic phases, and lamellar structures depending on the 
ratio of the components.  
The internal structure of a microemulsion vehicle is very important for the 
diffusivity of the phases, and thereby also for the diffusion of a drug in the 
respective phases. Researchers have been trying zealously to understand the 
complicated phase behaviour and the various microstructures encountered in the 
microemulsion systems.  
 
 
1.2.12. Components of Microemulsion Formulations17 
A large number of oils and surfactants are available which can be used as 
components of microemulsion systems but their toxicity, irritation potential and 
unclear mechanism of action limit their use. One must choose materials that are 
biocompatible, non-toxic, clinically acceptable, and use emulsifiers in an 
appropriate concentration range that will result in mild and non-aggressive 
microemulsions. The emphasis is, therefore, on the use of generally regarded as 
Safe (GRAS) excipients. 
Oil Phase:  
The oil component influences curvature by its ability to penetrate and 
hence swell the tail group region of the surfactant monolayer. Short chain oils 
penetrate the tail group region to a greater extent than long chain alkanes, and 
hence swell this region to a greater extent, resulting in increased negative 
curvature (and reduced effective HLB). Saturated (e.g. lauric, myristic and capric 
acid) and unsaturated fatty acids (e.g. oleic acid, linoleic acid and linolenic acid) 
have penetration enhancing property of their own and they have been studied 
since a long time. Fatty acid esters such as ethyl or methyl esters of lauric, 
myristic and oleic acid have also been employed as the oil phase. Lipophilic drugs 
are preferably solubilized in o/w microemulsions. The main criterion for selecting 
the oil phase is that the drug should have high solubility in it. This will minimize 
the volume of the formulation to deliver the therapeutic dose of the drug in an 
encapsulated form. 
Surfactants: 
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The surfactant chosen must be able to lower the interfacial tension to a 
very small value which facilitates dispersion process during the preparation of the 
microemulsion and provide a flexible film that can readily deform around the 
droplets and be of the appropriate lipophilic character to provide the correct 
curvature at the interfacial region.  
It is generally accepted that low HLB surfactants are favoured for the 
formulation of w/o microemulsion, whereas surfactants with high HLB (>12) are 
preferred for the formation of o/w microemulsion. Surfactants having HLB greater 
than 20 often require the presence of co-surfactants to reduce their effective HLB 
to a value within the range required for microemulsion formation. 
Co-surfactants: 
In most cases, single-chain surfactants alone are unable to reduce the o/w 
interfacial tension sufficiently to enable a microemulsion to form. The presence of 
co-surfactants allows the interfacial film sufficient flexibility to take up different 
curvatures required to form microemulsion over a wide range of composition. If a 
single surfactant film is desired, the lipophilic chains of the surfactant should be 
sufficiently short, or contain fluidizing groups (e.g. unsaturated bonds). Short to 
medium chain length alcohols (C3-C8) are commonly added as co-surfactants 
which further reduce the interfacial tension and increase the fluidity of the 
interface.  
1.2.13. Method of preparation of Microemulsion18 
1. Phase Titration Method 
Microemulsions are prepared by the spontaneous emulsification method 
(phase titration method) and can be depicted with the help of phase diagrams. 
Construction of phase diagram is a useful approach to study the complex series of 
interactions that can occur when different components are mixed. Microemulsions 
are formed along with various association structures (including emulsion, 
micelles, lamellar, hexagonal, cubic, and various gels and oily dispersion) 
depending on the chemical composition and concentration of each component. 
The understanding of their phase equilibria and demarcation of the phase 
boundaries are essential aspects of the study.  
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As quaternary phase diagram (four component system) is time consuming 
and difficult to interpret, pseudo ternary phase diagram is often constructed to find 
the different zones including microemulsion zone, in which each corner of the 
diagram represents 100% of the particular component .The region can be 
separated into w/o or o/w microemulsion by simply considering the composition 
that is whether it is oil rich or water rich. Observations should be made carefully 
so that the metastable systems are not included. 
2. Phase Inversion Method 
Phase inversion of microemulsions occurs upon addition of excess of the 
dispersed phase or in response to temperature. During phase inversion drastic 
physical changes occur including changes in particle size that can affect drug 
release both in vivo and in vitro.  
This method is referred to as phase inversion temperature (PIT) method. 
Instead of the temperature, other parameters such as salt concentration or pH 
value may be considered as well instead of the temperature alone. Additionally, a 
transition in the spontaneous radius of curvature can be obtained by changing the 
water volume fraction. By successively adding water into oil, initially water 
droplets are formed in a continuous oil phase. Increasing the water volume 
fraction changes the spontaneous curvature of the surfactant from initially 
stabilizing a w/o microemulsion to an o/w microemulsion at the inversion locus.  
Microemulsions can be prepared by controlled addition of lower alcohols 
(butanol, pentanol and hexanol) to milky emulsions to produce transparent 
solutions comprising dispersions of either water-in-oil (w/o) or oil-in-water (o/w) 
in nanometer or colloidal dispersions (~ 100 nm). The lower alcohols are called 
co-surfactants; they lower the interfacial tension between oil and water 
sufficiently low for almost spontaneous formation. The miscibility of oil, water 
and amphiphile (surfactant plus co-surfactant) depends on the overall composition 
which is system specific. 
Microemulsions also have industrial applications, one of them being the 
synthesis of polymers. Microemulsion polymerization is a complex heterogeneous 
process where transport of monomers, free radicals and other species (such as 
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chain transfer agent, co-surfactant and inhibitors) between the aqueous and 
organic phases, takes place. Compared with other heterogeneous polymerization 
processes (suspension or emulsion) microemulsion polymerization is a more 
complicated system. Polymerization rate is controlled by monomer partitioning 
between the phases, particle nucleation, and adsorption and desorption of radicals. 
Particle stability is affected by the amount and type of surfactant and pH of 
dispersing medium.  
1.2.14. Types of Microemulsions19 
1. O/W Microemulsion 
2. W/O Microemulsion 
3. Bi-continuous Microemulsion 
 
 
 
Fig 6: Types of Microemulsions 
 
Oil in Water Microemulsions: 
 Oil droplets are dispersed in the continuous aqueous phase. The o/w 
systems are interesting because they enable a hydrophobic drug to be more soluble 
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in an aqueous based system, by solubilizing it in the internal oil droplets. Most 
drugs tend to favor small/medium molecular volume oils as opposed to 
hydrocarbon oils due to the polarity of the poorly water-soluble drugs.  
Water in Oil Microemulsions: 
Water droplets are dispersed in the continuous oil phase. Water-in-oil 
microemulsions are made up of droplets of water surrounded by an oil continuous 
phase. These are generally known as “reverse-micelles”, where the polar head 
groups of the surfactant are facing into the droplets of water, with the fatty acid 
tails facing into the oil phase.  
 
Bi-continuous Microemulsions: 
            Micro domains of oil and water are interdispersed within the system. A 
bicontinuous microemulsion system both water and oil exist as a continuous 
phase. Irregular channels of oil and water are intertwined, resulting in what looks 
like a “sponge-phase”.  
 
1.2.15. Factors affecting the Microemulsion Formulations20 
 The formation of microemulsion will depend on the following factors 
a. Packing ratio:  
The HLB of surfactant determines the type of microemulsion through its 
influence on molecular packing and film curvature. The analysis of film curvature 
for surfactant association's leadings to the formation of microemulsion. 
b. Property of surfactant, oil phase and temperature:  
The type of microemulsion depends on the nature of surfactant. Surfactant 
contains hydrophilic head group and lipophilic tail group. The areas of these 
group, which are a measure of the differential tendency of water to swell head 
group and oil to swell the tail area are important for specific formulation when 
estimating the surfactant HLB in a particular system.  
When a high concentration of the surfactant is used or when the surfactant 
is in presence of salt, degree of dissociation of polar groups becomes lesser and 
resulting system may be w/o type. 
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Diluting with water may increase dissociation and leads to an o/w system. 
Ionic surfactants are strongly influenced by temperature. It mainly causes 
increased surfactant counter ion dissociation. The oil component also influences 
curvature by its ability to penetrate and hence swell the tail group region of the 
surfactant monolayer. Short chains oils penetrate the lipophilic group region to a 
great extent and results in increased negative curvature.  
Temperature is extremely important in determining the effective head 
group size of nonionic surfactants. At low temperature, they are hydrophilic and 
form normal o/w system. At higher temperature, they are lipophilic and form w/o 
systems. At an intermediate temperature, microemulsion coexists with excess 
water and oil phases and forms bicontinuous structure.  
c. The chain length, type and nature of co-surfactant:  
Alcohols are widely used as a co-surfactant in microemulsions. Addition 
of shorter chain co-surfactant gives positive curvature effect as alcohol swells the 
head region more than tail region so, it becomes more hydrophilic and o/w type is 
favoured, while longer chain co-surfactant favours w/o type w/o type by alcohol 
swelling more in chain region than head region. 
 
Table 2: Marketed Product in Microemulsion Technique 
 
S.no. Drugs Marketed products 
1. Cyclosporine Neoral 
2. Ibuprofen Solvium 
 
1.3. Arthritis21  
Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes 
inflammation of the joints and may cause inflammation of other tissues in the 
body.   The immune system consists of the cells and proteins in our bodies that 
fight infections.  An autoimmune disease occurs when our immune system doesn’t 
recognize part of our body and attacks it as if it were an invader such as a bacteria 
or virus.  
 In rheumatoid arthritis, the immune system targets synovial membrane 
and attacks it.  The synovial membrane is secretes synovial fluid into the joint.  
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Synovial fluid is the joint fluid that lubricates and nourishes the joint.  Other 
tissues can also be targeted by the immune system in rheumatoid arthritis, but the 
synovium, or synovial membrane, is generally the primary target.  When the 
synovial membrane is attacked, it becomes inflamed (synovitis) and can thicken 
and erode.  As the synovial membrane is destroyed, the synovial fluid fluid is also 
destroyed because it is not being secreted.  The surrounding structures can also 
become involved leading to the joint deformities that can be seen in rheumatoid 
arthritis. 
 
       Fig 7: Rheumatoid Arthritis  
1.3.1. Epidemiology of RA 
• RA affects over 21 million people worldwide 
• There are about 3 million people living with RA in Europe 
• RA affects 3 times as many women as men  
• Obesity 
• Previous joint injury 
• Ethnic background 
• It can affect people of all ages but it is most common in the 30-
50 age range 
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Fig 8: Prevalence of RA in Men, Overall and Women  
1.3.2. Types of Arthritis22 
 Based on the causes of arthritis changes, several forms of arthritis can be 
named. A particular type of arthritis occurs in a particular age group and in a 
particular joint. 
   Table 3: Types of Arthritis 
Arthritis Age Group Site 
Osteoarthritis Elderly Knee, lower back, 
Fingers 
Juvenile Rhumatoid 
arthritis 
Childhood Knee, hip 
Septic arthritis Childhood Knee, hip 
Rhumatoid arthritis Young adults Hip, Knuckles, Knee 
Ankylosing spondylitis Young adults Lower back, Cheast 
Psoriatic arthritis Young adults Knee 
Traumatic arthritis Any Any (Commonly knee, 
hip, ankle) 
Gout Young adults Big toe, knee 
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1.3.3. Clinical Features 
- The stiffness is characteristically worse in the morning and improves 
during the day; its duration is a useful indicator of the activity of the 
disease. The stiffness may recur especially after strenuous active. 
- The usual joints affected by rheumatoid arthritis are the 
metacarpophalangeal joints, the PIP joints, the wrists, knees, ankles 
and toes. 
- Entrapment syndromes may occur especially carpal tunnel syndrome 
 
• 20% of patients with RA will have subcutaneous nodules, usually seen 
over bony prominences but also observed in bursa and tendon sheaths; 
these nearly always occur in seropositive patients as do most other extra-
articular manifestations  
• Splenomegaly and lymphadenopathy can occur 
• Low grade fever, anorexia, weight loss, fatigue and weakness can occur 
• After months to years, deformities can occur; the most common are 
- Ulnar deviation of the fingers 
- Swan neck deformity, which is hyperextension of the distal 
interphageal joint and flexion of the proximal interphalangeal joint 
- Boutonniere deformity, which is flexion of the distal interphalangeal 
joint and extension of the proximal intraphalangeal joint valgus 
deformity of the knee. 
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1.3.4. Etiology for Arthritis23 
There are two main groups of theories’ regarding this disease 
1. That it is non-infective in character 
2. That it is infective 
The former postulates that the disease can manifest itself in the absence of 
organisms that, it is essentially due to disordered body chemistry.   
The latter holds that whether tissue changes resulting from non bacterial 
cause are present or not, it is essential that organisms be present locally. 
Non infective character falls into three groups 
1. Congential predisposition 
2. Endocrine disturbance 
3. Faulty alimentation 
 
  
 Fig 9: Difference between Normal joints and Rheumatoid Arthritis joints  
 
 Synovial macrophages and fibroblasts interact to perpetuate inflammation 
most of our knowledge of the inflammatory process and cellular infiltrate in the 
rheumatoid joint comes from the study of synovium in established, rather than 
early, disease, CD4 T cells and monocytes-macrophages migrate into, and remain 
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in the synovial interaction of cellular adhesion molecules with counterligands 
expressed on extracellular matrix molecules (e.g., collagen, fibronectin).  
 Neutrophils, in contrast, are found almost exclusively in the synovial 
cavity (fluid) and only rarely in the synovial tissue. Their migration through the 
synovial interstitium and across the synovial lining into the joint cavity may 
reflect lack of expression of specific adhesion molecules for extracellular matrix 
constituents. 
 
 
   
    
 
 
 
              Fig 10:  Pathogenesis of Rheumatoid Arthritis 
 According to the “T cell centric”   theory of RA, activation of CD4 cells 
would trigger and maintain the inflammatory process in the rheumatoid joint 
Interestingly, although large numbers of CD4 cells persist in the    synovium 
throughout the disease course, they appear to be inactive in the chronic phase of 
the disease. For example, expression of surface antigens (such as IL2 and 
transferrin receptors), and secretion of specific cytokines (e.g., IL2, IL4 and g-
IFN), that are associated with an activated T cell state are very low. 
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Table 4: Cellular sources of synovial cytokines in RA 
 
 
 
Products of  T cells 
IL-2 
IL-3 
IL-4 
IL-6 
IFNg 
TNFb 
GM-CSF 
In contrast, cytokines known to be produced primarily by “effector” cells 
(macrophages) and connective tissue cells (fibroblasts) are expressed in 
abundance in RNA synovium and synovial fluid , as measured by ELISA or 
mRNA studies. These cytokines include IL1, IL6, IL8 and GM – CSF. According 
to the alternative theory (the “macrophage –fibroblast theory”) of RA, these two 
cell types appear to be largely responsible for creating a self perpetuating state of 
chronic inflammation in which T cell participation may no longer be critical. In 
this scenario, the activated macrophage continuously secretes IL-1 and TNF 
which maintain the synovial fibroblast in an activated state. 
 
           Fig 11: Synovitis in RA patients 
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The fibroblast, in turn, secretes large amounts of: a) cytokines – IL6, IL8 
and GM-CSF; b) prostaglandins; c) protease enzymes. GM-CSF feeds back to 
promote the maturation of newly recruited monocytes to macrophages.IL-8 and 
IL-6 contribute to the recruitment and/or activation of yet other cell populations, 
while the prostaglandins and proteases act directly to erode and destroy nearby 
connective tissues such as bone and cartilage. 
1.3.5. Inflammatory Mediators in RA 
 In addition to activating synovial cells to secrete inflammatory mediators, 
IL-1 and TNF also have profound systemic effects. 
Table 5: Mediators in RA 
Cellular Systemic 
• Upregulation of adhesion molecules 
• Costimulant for T cells 
• Induction of prostanoid synthesis 
• Induction of cytokine synthesis (IL-6, 
IL-8, GMCSF) 
S 
• Fever 
• Decreased appetite 
• Muscle wasting 
 
 Some of these systemic effects are mediated via the induction of IL-6 
synthesis. Mature plasma cells that secrete rheumatoid factor are another 
prominent cellular component of rheumatoid synovium.  
 The stimulus for maturation of B cells to immunoglobulin-secreting 
plasma cells has classically been ascribed to CD4 T cells; however, as already 
noted CD4 T cells are not activated in the chronic phase of rheumatoid arthritis. 
IL-6, however, is a potent stimulus for maturation of B cells to plasma cells. Thus, 
synovial fibroblasts are likely providing the “T cell independent” stimulus for 
continuous plasma cell activation and rheumatoid factor production. IL-6 also 
suppresses albumin synthesis by the liver and stimulates acute phase protein 
synthesis. IL-6, therefore, contributes significantly to ESR elevation. 
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                            Table 6: Effects of IL-6 
                                                     Effects of IL-6 
B cell maturation Ig, rheumatoid factor ,  hypergammaglobulemia 
 
Hepatocyte stimulus Acute phase proteins (high ESR) 
Decreased albumin synthesis 
  
 Neutrophils are recruited in very large numbers to the rheumatoid cavity 
where they can be aspirated in the synovial fluid. Complement activation is not a 
prominent feature of RA. Therefore, C5a is unlikely to contribute significantly to 
the recruitment of neutrophils to the joint. IL-8, however, is also a potent and 
specific chemotactic stimulus for neutrophils.  
 Since synovial fibroblasts line the Joint cavity, their elaboration of this 
cytokine into the joint cavity is likely to explain the selective requirment of 
neutrophils to the synovial cavity. neutrophils in the synovial fluid are in an 
activated state, releasing oxygen-derived free radicals that depolymerize 
hyalurionic acid and inactivate endogenous inhibitors of proteases, thus promoting 
damage to the joint. 
 Prostaglandins and proteases are also secreted from synovial fibroblasts as 
the pannus invades contiguous bone and cartilage. PGE2  resorbs bone and 
contributes to the radiographically demonstrable erosions at the site of synovial 
bone attachment. The proteases (collagenase, stromelysin and gelatinase) act 
enzymatically to degrade the collagen and proteoglycan matrix of bone and 
cartilage.  
This destructive effect is further compounded by IL1 (and TNF ) which 
suppresses synthesis of these matrix molecules. Thus, IL1 provides a “double 
insult” to connective tissue by both promoting its degradation (by inducing  
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synthesis of proteases) and preventing its repair (by suppressing synthesis of 
collagen and proteoglycans). 
 
 
 
 
 
 
 
Fig 12:  Normal view joint 
 
A joint affected by arthritis loses its ability to provide smooth movement 
between the bones .this is because of the following changes taking place gradually 
over a period of time.  
• Decrease in the amount of synovial fluid  
• Wear and tear of articular cartilage 
• Thickness and stiffness of synovium 
• Stiffness and of the joint capsule 
These changes can occur due to several reasons like ageing, autoimmune 
disorders (immune system destroys our own body), genetic disorders, traumatic 
incident (accident, fall, or blunt injury), infection, and so on. 
  The arthritic changes are generally permanent and cannot be reversed 
after a period of time. Hence, early recognition and treatment is the only way to 
prevent more damage. 
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1.3.6. Symptoms of Rheumatoid Arthritis 
 The hallmark symptom of RA is morning stiffness that lasts for at least an 
hour. (stiffness from osteoarthritis , for instance , usually clears up within half an 
hour ).even after remaining motionless for a few moments , the body can stiffen. 
Movement becomes easier again after loosening up. 
 
Fig 13: Symptoms of RA 
Swelling and pain:   
 Swelling and pain in the joints must occurs for atleast six weeks before a 
diagnosis of RA is consider the inflamed joints usually swollen and often feel 
warm and “boggy” when touched .The pain often occurs symmetrically but may 
be more severe on one side of the body , depending on which hand the person 
uses more often(Fig 13). 
Specific joints affected:   
 Although RA almost always develops in the wrists and knuckles , the 
knees and joints of the ball of the foot are often affected as well .Indeed ,many 
joints may be involved ,including those in the cervical spine , shoulders ,elbows, 
tips , temperomandibular joint (jaw) , and even joints between very small bones 
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in the inner ear . RA does not usually show up in the fingertips,where 
osteoarthritis is common , but joints at the base of the fingers are often painful . 
Nodules:  
 Nodules can occur throughout the course of the disease. Rarely, nodules 
may become sore and infected, particularly if they are in locations where stress 
occurs, such as the ankles. On rare occasions, nodules can reflect the presence of 
rheumatoid vasculitis, a condition that can affect blood vessels in the lungs, 
kidneys, or other organs. 
Fluid Buildup:  
 Fluid may accumulate, particularly in the ankles. In the joint sac behind 
the knee accumulates fluid and forms what is known as a Baker cyst. This cyst 
feels like a tumor and sometimes extends down the back of the calf causing pain. 
Baker cysts often develop in people who do not have RA. 
Flu-Like Symptoms: 
 Symptoms such as fatigue, weight loss, and fever may accompany early 
RA, some people describe them as being similar to those of a cold or flu except, 
of course, RA symptoms can last for years. 
Symptoms in children: 
 In children, juvenile RA, also known as still’s disease, is usually preceded 
by high fever and shaking chills along with pain and swelling in many joints. A 
pink skin rash may be present.    
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1.3.7. Medications 
 
Fig 14: Medication of RA 
Many drugs used to treat rheumatoid arthritis have potentially serious side 
effects. Doctors typically prescribe medications with the fewest side effects 
first. You may need stronger drugs or a combination of drugs as your disease 
progresses. 
NSAIDS:  
 Enolic acid (Oxicam) derivatives 
o Piroxicam 
o Meloxicam 
o Tenoxicam 
o Droxicam 
o Lornoxicam 
o Isoxicam 
 
Mechanism of Action79 
Lornoxicam   act as nonselective inhibitors of the enzyme cyclooxygenase 
(COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
(COX-2) isoenzymes. COX catalyzes the formation of prostaglandins and 
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thromboxane from arachidonic acid (itself derived from the cellular phospholipid 
bilayer by phospholipase A2).  
Prostaglandins act (among other things) as messenger molecules in the process 
of inflammation. NSAIDs have antipyretic activity and can be used to treat fever. 
Fever is caused by elevated levels of prostaglandin E2, which alters the firing rate 
of neurons within the hypothalamus, that control thermoregulation. Antipyretics 
work by inhibiting the enzyme COX, which causes the general inhibition of 
prostanoid biosynthesis (PGE2) within the hypothalamus.  
PGE2 signals to the hypothalamus to increase the body's thermal set point. 
Ibuprofen has been shown to be more effective as an antipyretic than 
acetaminophen. Arachidonic acid is the precursor substrate for cyclooxygenase 
leading to the production of prostaglandins F, D & E. 
1.3.8. Inflammation25 
  Inflammation (Latin, inflammo, "I ignite, set alight") is part of the 
complex biological response of vascular tissues to harmful stimuli, such as 
pathogens, damaged cells, or irritants (Fig 15).  Inflammation is a protective 
attempt by the organism to remove the injurious stimuli and to initiate the healing 
process. Inflammation is not a synonym for infection, even in cases where 
inflammation is caused by infection.  
Although infection is caused by a microorganism, inflammation is one of 
the responses of the organism to the pathogen. However, inflammation is a 
stereotyped response, and therefore it is considered as a mechanism of innate 
immunity, as compared to adaptive immunity, which is specific for each pathogen.  
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    Fig 15: Inflammation 
1.3.9. Classification of Inflammation  
 Inflammation can be classified as either acute or chronic. Acute 
inflammation is the initial response of the body to harmful stimuli and is achieved 
by the increased movement of plasma and leukocytes (especially granulocytes ) 
from the blood into the injured tissues. A cascade of biochemical events 
propagates and matures the inflammatory response, involving the local vascular 
system, the immune system, and various cells within the injured tissue. Prolonged 
inflammation, known as chronic inflammation, leads to a progressive shift in the 
type of cells present at the site of inflammation and is characterized by 
simultaneous destruction and healing of the tissue from the inflammatory process. 
 
1.3.10. Symptoms of Inflammation 
¾ Redness 
¾ Swollen joint that's tender and warm to the touch 
¾ Joint pain 
¾ Joint stiffness 
¾ Loss of joint function 
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Fig 16: Mechanism of inlammation 
1.3.11. Anti- inflammatory Effects23 
Many mediators coordinate inflammatory and allergic reaction. While 
some are produced in response to specific stimuli (e.g. Histamine in allergic 
inflammation) there is considerable redundancy, and each facet of response –
vasodilatation, increased vascular permeability, cell accumulation, etc-can be 
produced by several separate mechanisms. 
The NSAIDS reduce mainly those component of the inflammatory and 
immune response in which prostaglandin, mainly derived from COX -2, play a 
significant part .These include: 
• Vasodilatation  
• Oedema (by an indirect action; the vasodilatation facilities and 
potentiating the action of mediators such as histamine that increase the 
permeability of postcapillary venules  
• Pain ,again potentiating other mediators ,such as bradykinin  
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The NSAIDs suppress the pain, swelling and increasing blood flow associated 
with inflammation but have little or no action on the actual progress of the 
underlying chronic disease itself. As a class, they are generally without effect on 
other aspects of inflammation, such as leucocytes migration, lysosomal enzyme 
release and toxic oxygen radical production that contribute to tissue damage in 
chronic inflammatory conditions such as rheumatoid arthritis, vasculitis and 
nephritis. 
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2. LITERATURE REVIEW 
According to the aim and objectives my research work I have reviewed the 
following literatures as support for the delivery system and diseases to carry out 
the project to its logical conclusion.  
 2.1 Literature review for Microemulsions 
26Jadupati et al., 2011 developed the Insulin-loaded microemulsions for 
transdermal delivery using isopropyl myristate or oleic acid as the oil phase, 
Tween 80 as the surfactant, and isopropyl alcohol as the co-surfactant. The insulin 
permeation flux of microemulsions containing oleic acid through excised mouse 
skin and goat skin was comparatively greater than that of microemulsions 
containing isopropyl myristate. The insulin-loaded microemulsion containing 10% 
oleic acid, 38% aqueous phase, and 50% surfactant phase with 2% dimethyl 
sulfoxide (DMSO) as permeation enhancer showed maximum permeation flux 
(4.93 ± 0.12 g/cm2/hour) through goat skin. The in vitro insulin permeation from 
these microemulsions was found to follow Zero order and the Korsmeyer-Peppas 
model (R2 = 0.923 to 0.973) over a period of 24 hours. 
27Bhavika et al., 2011 developed a microemulsion for enhancing the 
permeation of acyclovir using different penetration enhancer like DMSO, 
Menthol, and Eucalyptus oil. They concluded that 1% menthol incorporated as a 
penetration enhancer and it showed 10% increase in permeation rate of drug. The 
microemulsion system was investigated for viscosity, pH, refractive index, 
electrical conductivity, and permeation. The optimum formulation provided 76% 
drug release in 12 hr. 
28Xiaohui et al., 2011 studied the microstructure characterization of 
microemulsion consisting of oleic acid, cremophor RH40, ethanol and water and 
investigate the influence of microstructure on the solubilization potential of the 
microemulsion to meloxicam. They concluded that the solubilization capacity of 
microemulsion is closely related with its microstructure. The solubilization of 
W/O microemulsion is the best, compared with other two (O/W, Bi continuous), 
where as the O/W is the weakest. 
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29Ying   et al., 2011 investigated a microemulsion system for transdermal 
delivery of ligustrazine phosphate. Microemulsions containing isopropyl 
myristate, labrasol, plurol oleique® and water were investigated in pseudo-ternary 
phase diagrams. The optimized microemulsion with permeation flux of 41.01 
µg/cm2/h across rat skin in vitro, showed no obvious irritation on back skin of 
rabbits. The results indicated that the studied microemulsion system might be a 
promising vehicle for transdermal delivery of ligustrazine phosphate. 
30Manish  et al., 2010 formulated Glipizide Microemulsion by water 
titration method using oleic acid as oil phase, tween-80 as surfactant and 
propylene glycol as co-surfactant. Microemulsions were characterized for pH, 
viscosity, droplet size, in vitro release profile, ex-vivo diffusion study, irritancy 
tests, stability and in vivo evaluation. Five microemulsion formulations were 
prepared.Oleic acid is used as oil phase in 2, 4, 6, 8, 10% concentration of 
formulation content and then 6% (ME-3) obtained in clear form and have higher 
cumulative percent release than others. Non–ionic surfactant Tween-80 was 
selected because they are generally less toxic, produce less skin irritation. In vivo 
studies were carried out on wistar rats. The optimized microemulsion formulation 
was found to be o/w type emulsion and having mean particle size of 138±4.5 nm.  
The results indicated that the developed microemulsion systems, especially ME-3, 
may be promising vehicles for the transdermal delivery of glipizide.  
31Brajesh et al., 2010 developed o/w microemulsion for transdermal 
delivery of poorly water soluble acyclovir by aqueous titration method. 
Characterization of microemulsion were done for droplet Shape and size, 
refractive index, pH, Viscosity, drug loading capacity.  Oleic acid is a model skin 
permeation enhancer for transdermal drug carrier and poorly water soluble drug. 
The mean droplet size of microemulsion was found below 50 nm.  The surface 
morphology of microemulsion was evaluated by TEM. They concluded that The 
drug loaded microemulsion oily phase droplets shapes were found to be spherical, 
the range of 41.91 to 52.79 nm. The viscosity values of all samples were low and 
relatively constant at 33.28 to 41.01 mP. All samples exhibited Newtonian flow 
behaviour, as expected from microemulsions. 
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32Kalra et al., 2010  developed  aceclofenac microemulsion formulations  
to increase the effect, controlled permeation, increased drug solubilization 
capacity and to minimize oral side effects of drug. Investigated the potential of 
microemulsion gel formulation using nonirritating and pharmaceutically 
acceptable ingredients without using additional harmful permeation enhancers. 
 Permeation rate of aceclofenac evaluated by Keshary Chein diffusion cell which 
confirmed that drug can easily permeate through the skin due to small particle size 
of microemulsion.  In vivo studies of drug molecule was done by anti-
inflammatory (Acute) model and FCA (Chronic) model which indicated that 
effect of drug was enhanced by prepared microemulsion and microemulsion gel.  
33Anjali CH et al., 2010 investigated the antibacterial activity of refined 
Sunflower oil, Tween 20, water microemulsion system. Pseudo‐ternary phase 
diagram were constructed to obtain the concentration range of oil, surfactant and 
water. Three microemulsion formulations were prepared. The concentration of 
refined sunflower oil varied from 5 % to 15 %, the surfactant concentration varied 
from 10 % to 30 % and water concentration varied from 55 % to 85 %. When 
water concentration increased, conductivity of the microemulsion system 
increased upto 50 % of water concentration and after that become stable. When oil 
and surfactant concentration was increased, pH of the microemulsion system 
decreased. 
34Mrunali  et al., 2010 investigated the effect of vehicle on in vitro skin 
permeation of ketoconazole applied in o/w microemulsions. The optimized 
microemulsion formulation showed a highest permeation rate of 63.28 ± 4.93 µg 
cm2 h. Candida Albicans were used as a model fungus to evaluate the antifungal 
activity of the best formula achieved. These results indicate that the studied 
microemulsion formulation might be a promising vehicle for future topical 
delivery of KTZ. 
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35Fathy  et al., 2010 Determined the in vitro release of piroxicam in 
microemulsion formulations in different gel bases, such as, methyl cellulose 
(MC), carboxy methyl cellulose (CMC), hydroxypropyl methyl cellulose 
(HPMC), Carbopol 934, Carbopol 940, and Pluronic F-127 bases. The drug 
content of piroxicam, pH and viscosity was measured. The results showed that, 
the incorporation of piroxicam in microemulsion formulas could lead to 
enhancement of piroxicam release profiles by allowing constant and regular in 
vitro release. Three percent MC gel base showed the highest release of piroxicam-
microemulsion after 180 min (97.70%) followed by 3% HPMC (94.0%) when 
compared to bases containing piroxicam alone. 
36Tian et al., 2009 designed the Microemulsion System for Transdermal 
Drug Delivery of Amphotericin B using isopropyl myristate (IPM), Tween 80, 
isopropyl alcohol and water. The pseudo-ternary phase diagrams were constructed 
by the H2O titration method and the structures of the microemulsion were 
determined by measuring electrical conductivities. The diffusion studies were 
performed via excised rabbit skin. At pH 5.14, amb microemulsion with Km 1:1, 
O/SC 1:9(mass ratio of oil phase to surfactant/cosurfactant blend), water content 
64.6%, drug content (2.93±0.08) mg/ml, showed the maximum permeation rate 
(3.255±0.64) µg·cm−2·h−1, which is stable for a long time. 
37Rohit  et al., 2009  Prepared Five different Fluconozole formulations 
with various values of oil (5 – 25%), water (10 – 50%), and the mixture of 
surfactant and co-surfactant (at the ratio of 4) (45 – 65%). In-vitro permeation of 
fluconazole from the microemulsions was evaluated using Keshary Chien 
diffusion cells mounted with 0.45µ cellulose acetate membrane. The amount of 
drug permeated across was analyzed by HPLC and the droplet size and zeta 
potential of the microemulsions was characterized. The globule size ranged 
between 122 - 418nm. The permeability of optimised microemulsion formulation 
was increased approximately five folds than that of the marketed formulation. The 
results indicated that the microemulsion system studied would be a promising tool 
for enhancing the percutaneous delivery of fluconazole. 
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38Zhai et al., 2009 formulated Penciclovir Microemulsion- based hydrogel 
for topical delivery.  They compared the formulation with the commercial cream, 
microemulsion- based hydrogel and microemulsion significantly increased the 
permeation of the drug into both epidermis and dermis. After the characterization 
of the formulation they concluded that the microemulsion based hydrogel could be 
a promising vehicle for topical delivery of Penciclovir. 
39Arun et al., 2009 were formulated the two  novel formulation of O/W 
microemulsion of ketoprofen for improving transdermal absorption. Formulations 
were prepared by constructing the pseudo-ternary phase diagrams using oleic acid, 
polysorbate-80, propylene glycol and water in different ratios and were gelled by 
incorporating cab-o-sil. The result of solubility study shown ketoprofen was 
highest in oleic acid, followed by ethyl oleate, isopropyl myristate, and isopropyl 
palmitate. Therefore, oleic acid was chose as oil phase for microemulsion. The 
oily mixtures of oleic acid, polysorbate-80 and propylene glycol led to increased 
in drug solubility. After extensive screening for physical characteristics and 
appearance, final ratios of surfactants- cosurfactants were decided. In-vitro 
diffusion study was carried out using artificial semipermeable membrane. The 
percentage of drug release across the membrane from marketed product, 
formulation-1 and formulation-2 were found to be 84.64%, and 90.20% 
respectively in 8 hrs 
40Mostafa et al., 2008 were formulated fluoxetine hydrochloride as a 
microemulsion form for transdermal delivery using various ratio of surfactant. 
Characterization of selected MEs was achieved by pH determination, 
centrifugation, particle size and viscosity measurements, determination of 
refractive index and morphology studies using TEM. Five ME formulation were 
prepared and Selected ME3 was tested for its ability to penetrate through rat skin. 
ME3 exhibited an optimum composition with regard to stability, pH value, 
viscosity, and droplet size and permeation rate for effective in-vitro delivery 
across an artificial cellulose membrane; it also exhibited good penetration ability 
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through rat skin confirming its feasibility as a transdermal delivery system for 
fluoxetine hydrochloride. 
41 Gamal et al., 2008 self microemulsifying and microemulsion systems 
for transdermal delivery of Indomethacin: Effect of phase transition was studied 
by in their study they investigated five formulations with fixed surfactant-oil ratio 
and increasing water content. They concluded that these formulation increased the 
transdermal drug flux compared to saturated drug solution in Phosphate buffered 
saline. 
42Ambade et al., 2008 formulated and evaluated the Flurbiprofen 
Microemulsion using isopropyl myristate, Ethyl oleate as oils, aerosol OT as 
surfactant and  sorbitan monooleate as cosurfactant. Thye investigated that the 
formulation by pass its gastrointestinal adverse effects. They concluded that 
flubriprofen from optimized microemulsion formulation was found to be more 
effective as compared to gel cream in inhibiting the caragenan induced rat paw 
edema at all time intervals. 
43Gamal  et al., 2008 developed Transdermal delivery of hydrocortisone 
from eucalyptus oil microemulsion in which steroidal drug as oil, Tween 80 as 
surfactant, Ethanol, isopropanol, and propylene glycol as co surfactants. Pseudo 
ternary phase diagrams were constructed in the presence and absence of co 
surfactant. The presence of co-surfactant increased the transdermal drug flux 
compared to the co surfactant free formulation. Thus they concluded that the 
presence of co surfactants and its type can affect both the phase behavior and 
transdermal delivery potential of microemulsion. 
44Ke-Shu et al., 2007 evaluated the transdermal permeability of 
pentoxifylline gel in vitro and in vivo. Gel was prepared with carbomer 934 as the 
base, and the Wistar rat was chosen as an animal model. The effects of 
percutaneous enhancers on the transdermal permeability of pentoxifylline gel 
were investigated by in vitro permeation experiments. Cumulative permeation at 
different times was determined by HPLC. 3% Azone and 5% propylene glycol 
were used as collaborative enhancers in an optimal formulation. Topical 
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concentrations at different times were measured by microdialysis in vivo. The 
transdermal process of pentoxifylline fits to a zero-order kinetic equation, and its 
release profile remains of the zero-order despite the addition of enhancers. In 
addition, a good in-vitro-in-vivo correlation was achieved. 
 
45Anna et al., 2006 formulated a microemulsions as transdermal drug 
delivery vehicles by using oleic acid as permeation enhancers,L–α–
phosphatidylcholine from egg yolk. Thus they concluded microemulsion were 
found as an effective vehicle of the solubilization of certain drugs and as 
protecting medium for the entrapped of drugs from degradation,hydrolysis and 
oxidation.It can provide prolonged release of the drug and prevent irritation. 
46Huabing et al., 2006 were constructed microemulsion-base hydrogel 
formulation for topical delivery of ibuprofen ethyl oleate as oil phase, Tween 80 
as surfactant, propylene glycol as cosurfactant. They formulated various 
microemulsion formulations were prepared and the abilities of various 
microemulsions to deliver ibuprofen through the skin were evaluated in vitro. 
Thus the studied microemulsion-based hydrogel showed a good stability indicated 
that the studied microemulsion-based hydrogel may be a promising vehicle for 
topical delivery.  
47Gupta et al., 2005 designed and Testing of an effective oil-in-water 
microemulsion drug delivery system. They studied the new pseudoternary system 
of clove oil/Tween 20. Quarcetin drug was encapsulated in the vehicle and the 
hepatotoxicity of the vehicle with and without the drug was studied by estimating 
serum alkaline phosphates, glutamate pyruvate transaminase, urea and creatinine. 
48Haubing et al., 2004 studied microemulsion systems for transdermal 
delivery of triptolide posessesing immunosuppressive, anti-fertility and anti 
cancer activities. They formulated the microemulsion using oleic acid as oil phase, 
tween 80 as surfactant and propylene glycol as a cosurfactant. After the 
chacterization of the formulated microemulsion they concluded that this 
microemulsion is a promising vehicle for the transdermal delivery of triptolide. 
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49Fang et al., 2004 made lipid- nano/submicron emulsions were made of 
isopropyl myristate, soya bean oil or coconut oil as the oil phase lecithin as the 
surfactant. They evaluated the physiochemical and in vitro permeation and in vivo 
topical application of the formulation. Thus they concluded the feasibility of this 
formulation for the topical delivery of the flubriprofen. 
50Baroli et al., 2000 formulated and characterized the microemulsions for 
topical delivery of 8-methoxsalen using Tween-80, Span-80, 1, 2-Octanediol for 
the treatment of hyperprolioferative skin diseases. The formulations were 
characterized and thus they concluded that the microemulsion system may be 
appropriate vehicles for the topical delivery of 8- methoxsalen. 
51Mohammed et al., 2000 investicated the aerosol-OT 
(AOT)/water/isopropyl myristate microemulsion were investigated as a carrier in 
transdermal drug delivery of tetracaine hydrochloride. Studied in vivo analgesic 
on rats and histopathological, irritation, and oxidative stress measurements on 
mice. The tetracaine hydrochloride encapsulated in AOT/water/isopropyl 
myristate showed an eightfold enhancement in the analgesic response of drug 
compared to the aqueous solution of the drug as measured by the tail-flick 
method. The local analgesic response time of tetracaine hydrochloride was 
dependent on the composition of the microemulsion. The local analgesic 
responses of tetracaine hydrochloride increased as the weight percentage of AOT 
and water increased up to a certain concentration in the microemulsion. 
52Shaun et al., 1997 studied Ex-vivo permeation of indomethacin from a 
submicron emulsion through albino rabbit cornea.  Solubility of the formulation 
was pH dependent and the penetration rate of indomethacin through excised rabbit 
eye cornea from the emulsion and from a marketed product were determined and 
compared using a novel mounted corneal diffusion assembly. They concluded that 
the apparent corneal permeability coefficient of indomethacin incorporated in the 
emulsion was 3.8 times greater than that of indomethacin in the marketed aqueous 
solution. 
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2.2. Literature review for Lornoxicam 
53Kavitha K et al., 2011 developed and evaluated matrix-type transdermal 
Films containing Lornoxicam with different ratios of hydrophilic (Hydroxy Propyl 
methyl cellulose), and hydrophobic (Ethyl cellulose) polymers by the solvent 
evaporation technique. The prepared transdermal patches were evaluated for in 
vitro release, moisture absorption, moisture loss and mechanical properties. The 
diffusion studies were performed by using modified Franz diffusion cells. The 
drug release rate increased when the concentration of hydrophilic polymer was 
increased. 
54Parikh et al., 2011 formulated and evaluated Fast dissolving tablets of 
Lornoxicam were prepared by sublimation method and effervescent technique 
using various excipients (Menthol, camphor, Anhydrous sodium bicarbonate and 
citric acid respectively in different concentrations).The  concentration of 
subliming agents increased the disintegration time and wetting time of tablets was 
decreased in case of sublimation techniques. 
55Phani et al., 2011 prepared sustained release matrix tablets of 
Lornoxicam. The tablets were formulated by wet granulation method by using 
10%, 20%, 30%, and 40% Tamarind Seed Polysaccharide (TSP) as a natural 
binder and  compared with maximum ratio of various binders (HPMC K4M, 
Sodium CMC, Guar Gum). Concluded that drug release pattern was mainly 
dependent on the type of polymer, 20% TSP binder release the drug which 
followed zero order kinetics.  
56 Syed et al., 2011 formulated and Evaluated Sustained Release Matrix 
Tablets of Lornoxicam. Various formulations were developed by using release 
rate controlling and gel forming polymers like HPMC (K4M, K15M, K100M) in 
single by direct compression method. Different proportion of HPMC was 
associated with decrease in the overall cumulative drug release rate. The higher 
viscosity polymer had been seen to inhibit the initial burst release of Lornoxicam. 
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57Ganesh  et al., 2010   formulated chronomodulated drug delivery system 
of Lornoxicam to prolong its duration of action and thus reduce the frequency of 
usage and to minimize its irritant effect on the stomach. Microspheres of 
Lornoxicam were prepared by using polymers like Gelatin, Na CMC and 
Chitosan. 
58Sandeep  et al., 2010 studied design and evaluation of mucoadhesive bi-
layered buccal patches of lornoxicam. Bi-laminated films composed of drug 
(Lornoxicam) and chitosan, with (HPMC) and backing layer (ethyl cellulose). 
Films were fabricated by solvent casting technique.To increase HPMC 
concentration and increase folding endurance of the films. The swelling index 
increases with increase in HPMC concentration. 
59Bhavsar et al., 2010 development and validation of uv-
spectrophotometric Method for simultaneous estimation of paracetamol and 
Lornoxicam in bulk and tablet dosage form and concludes that simultaneous 
equation method is simple, precise, and accurate for the rapid determination of 
PARA and LOX in combined tablet dosage forms and this method may be 
successfully applied in control laboratories for their determination in combined 
dosage form.  
60Lakshmi   et al., 2010 studied simultaneous spetrometric estimation of 
paracetamol and lornoxicam in tablet dosage form and concludes that 
simultaneous and absorbance ratio methods were validated for linearity, accuracy 
and precision.   
61Rajesh et al., 2009 studied lornoxicam is extremely bitter in taste to 
develop a bitterless oral disintegrating tablet of lornoxicam, masking was done by 
Eudragit EPO in different ratios, In this superdisintegrants were used while 
preparing tablets and concluded that tablets shown good taste and disintegrantion 
in oral cavity. 
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62Berry et al., 1992 studied a double blind, multicentre, placebo controlled 
trial of lornoxicam in patients with osteoarthritis of the hip and knee and 
concluded that the lornoxicam was generally well tolerated, though some 
gastrointestinal side effects were seen as has been reported with other NSAIDs 
and no evidence of drug toxicity. 
2.3. Literature review for In vivo studies 
63Fathy I et al., 2011 designed to compare the anti‐inflammatory and 
analgesic effects of piroxicam in microemulsion formulation incorporated in 
different pharmaceutical gel bases to the commercial product (Feldene Gel®). The 
anti‐inflammatory activity of the tested piroxicam formulations was evaluated 
using right hind paw oedema size of rats induced by carrageenan injection, while 
the analgesic effect was evaluated using Hot Plate method applied on mice. 
produced a maximum percent oedema inhibition after 1 hr (75.7% and 76.90%), 
respectively, while the analgesic effect of the same previous formulae produce a 
maximum increase in reaction time (analgesic effect) but after 1.5 hr (62.8% and 
65.8% seconds) respectively, and then this analgesic effect was continued 
significantly for 3 hrs. indicating that the tested piroxicam formulations exhibited 
good and acceptable pharmacological effects (i.e. anti‐inflammatory and analgesic 
effects) in comparison to the commercial product (Feldene Gel®). 
64Nahla  et al., 2011 investigated the potential of microemulsion 
formulations for transdermal delivery of indomethacin were prepared by the 
spontaneous emulsification method, and characterized for morphology, droplet 
size, and rheological characteristics. The ex vivo skin permeation studies were 
performed using Franz diffusion cell with rabbit skin as a permeation membrane. 
The anti-inflammatory effects of microemulsion formulations showed a 
significant increase in percent edema inhibition value after 4 hours. It is promising 
that the concentration of indomethacin used to treat relative skin inflammatory 
conditions could be decreased due to the high permeation ability of indomethacin 
microemulsion and side effects of indomethacin might be reduced. Thus, this 
study suggests that, transdermal administration may be considered as an 
 LITERATURE REVIEW 
 
 49 
 
alternative noninvasive method for indomethacin delivery to achieve rapid onset 
of its pharmacological effects. 
65Ashutosh et al., 2008 Synthesis, Characterization and Pharmacological 
Evaluation of Amide Prodrugs of Flurbiprofen.They suggested retard the adverse 
effects of gastrointestinal origin. They subjected the synthessised prodrugs for 
bioavailability studies, analgesic, anti-inflammatory activities and ulcero genic 
index. Thus they concluded that these prodrugs can be considered for sustained 
release purpose. 
66Buritova J et al., 1998 evaluated the anti-inflammatory and analgesic 
effects of Lornoxicam in the carrageenan model of inflammatory nociception. 
They concluded   that Lornoxicam reduces the carrageenan- evoked odema at low 
doses of lornoxicam.   
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3. AIM AND OBJECTIVE   
The aim of my present study is to Develop and Evaluate Microemulsion 
for Transdermal Delivery of Lornoxicam by using oleic acid at different ratios for 
the treatment of Rheumatoid Arthritis and inflammation.  
Design of Microemulsion formulation for transdermal delivery of drugs, 
having the potential to increase the solubility of poorly water soluble drugs 
♣ To avoid the first pass metabolism and there is a potential to deliver the 
drug in a controlled manner 
♣ To have the possibility of immediate withdrawal of the treatment if 
necessary 
♣ To minimize the adverse effect on the g.i.t like mild dyspepsia and 
heartburn to ulceration and hemorrhage 
♣ Reduction of dosing frequency due to longer duration of action 
♣ To improve patient compliance  
♣ To achieve a continuous delivery of drugs at predictable and reproducible 
kinetics over an extended period of time in the circulation 
♣ To provide sustained release drug for longer periods of time due to short 
half life 
♣ To delivery of hydrophilic as well as lipophilic drug as drug carriers 
because of its improved drug solubilization capacity and long shelf-life 
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4. PLAN OF WORK 
¾ Title selection 
¾ Literature Review 
¾ Selection of drug and Excipients 
¾ Preformulation Study: 
a. Description 
b. Melting Point 
c. Solubility 
d. Hygroscopic Nature 
e. Identification of the drug 
• UV absorption maxima 
• FTIR studies 
f. Drug- Excipient compatibility studies by FTIR 
¾ Selection of Oil, Surfactant and Co-Surfactant  
¾ Trial Formulations 
¾ Optimization of Microemulsions 
¾ Selection of best formulation 
¾ Characterization of Microemulsions 
a. Optical Transparency 
b. Determination of pH 
c. Viscosity Measurements 
d. Mechanical Stress Study  
e. Drug Content Analysis 
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e. Particle Shape and Surface Morphology by  
1. Transmission Electron microscopy (TEM) 
2. Atomic Force Microscopy(AFM) 
f. Particle size Measurement by 
1. Particle size analyzer 
¾ Evaluation Studies: 
 In-Vitro Skin permeation study 
 In -Vivo study (Anti-inflammatory activity) 
¾ Release kinetics 
¾ Stability testing as per ICH guidelines 
¾ Results and Discussion 
¾ Conclusion   
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5. DRUG AND EXCIPIENT PROFILE  
 
5.1. LORNOXICAM66, 67 
 
Chemical Structure: 
 
 
Category  : Rheumatoid arthritis and osteoarthritis  
   Anti-inflammatory, antipyretic, and analgesic activities.  
Brand name  : Xafon, Lorcam 
Chemical name : 6-Chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-
                                      thien [2, 3,-e]-1, 2-thiazine-3-carboxamide 1, 1- dioxide. 
Empirical Formula : C13H10CLN3O4S2 
Molecular Weight : 371.82g/mol 
Description: 
Colour  : Yellow crystalline powder 
Taste   : weakly   acidic drug 
Solubility  : soluble – 0.1N hydrochloric acid and pH 7.4 
     slightly soluble - water and methanol 
PKa   : PKa of the lornoxicam is 24.7 
Storage  : Protected from light and moisture 
Bioavailability : 90-100% 
Metabolism  : CYP2C9 
Half life  : 4-5 hours 
Excretion  : 2/3hepatic, 1/3renal 
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Pharmacological actions68: 
 Lornoxicam inhibits prostoglantin biosynthesis by blocking the enzyme 
cyclooxygenase. Lornoxicam inhibits both isoforms in the same concentration 
range, that is, COX-1 inhibition: COX-2 inhibition = 1. Lornoxicam synovial 
fluid: plasma AUC ratio is 0.5, after administration of 4 mg twice daily. 
 
Interactions: 
Drug Interaction 69: 
Table 7: Drug Interaction with Lornoxicam 
 
Drugs 
 
 
Drug interactions 
Blood pressure medication Reduced pressure lowering effect 
 
Alcohol Potential gastrointestinal symptoms 
 
Warfarin 
 
Risk of bleeding 
Asthma medication 
 
Reduced effect of asthma medication; risk 
of asthma attack 
Cardiac glycosides, digoxin Risk  that heart failure may be more severe 
 
Corticosteroids potential gastrointestinal symptoms 
 
Cholestyramine Reduced effect of Lornoxicam 
 
Ciclosporin Potential Lornoxicam toxicity 
 
Methotrexate Potential  methotrexate toxicity 
 
Diuretics Potential risk of kidney damage 
 
Baclofen Potential baclofen toxicity 
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Disease interactions70: 
 Consult your doctor before using this drug if you have asthma, a stomach 
ulcer, a bleeding disorder, you are taking blood thinning medication or if you are 
allergic to aspirin or any other medication. 
Recommended dosage: 
 Adults: 8-16mg/day in 2-3 divided doses. 
Contraindications71: 
The drug is contraindicated in patients that must not take other NSAID’S 
possible reasons including salicylate sensitivity, gastrointestinal bleeding and 
bleeding disorder and severe impairment of heart, liver or kidney function. 
Lornoxicam is not recommended and is contraindicated during the last third of 
pregnancy.     
Adverse effect72: 
 Lornoxicam has side effects similar to other NSAID’S most commonly 
mild once like gastrointestinal disorders (nausea and diarrhea) and headache. 
Severe but seldom side effects include bleeding, bronchospasms and the 
extremely rare Stevens – Johnson syndrome. 
Warning: 
 Do not use lornoxicam in children under the age of 18. According to 
Nycomed.com, in the event of an overdose, the user will experience more severe 
forms of the side effects. In the event of a real or suspected overdoses, contact 
your doctor immediately. Never use lornoxicam if you have a history of liver 
conditions, ulcers or blood coagulation problems. 
Common Side effects: 
 The most common side effects reported with the regular use of the tablet 
form of lornoxicam include dizziness, headache, stomach pain, upset stomach, 
diarrhea, nausea, vomiting and indigestion. As an injection, user most commonly 
report headache, flushing, insomnia and redness and irritation at the injection spot. 
Though common and less serious than other effects, these side effects are cause 
for concern if they worsen or occur regularly. In such an event, contact your 
doctor.   
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5.2. EXCIPIENT PROFILE 
5.2.1 Oleic Acid73, 74, 75 
Chemical structure:   
 
Molecular Formula  :  C18H34O2 
Synonyms   :  Ethyl 9-octadecenoate, Kessco EO 
Chemical name  :  (Z)-9-Octadecenoic acid, ethyl ester 
Non Proprietary Name 
BP, USP   :  Oleic acid 
Ph Eur   :  Acidum oleicum   
Molecular Weight  :  282.4614 g/mol  
Functional Category  :  Skin penetrant, Emulsifying agent 
Description   :  Pale yellow or brownish yellow oily liquid 
                            with lard-like odor  
Solubility   :  Soluble in acetone, chloroform, ether, 
                            Insoluble in water. 
Pharmacopeial Specifications:  
Specific gravity   :  0.866–0.874  
Viscosity   : 5.15 mPa s  
Refractive index  :  1.443–1.450  
Acid value   :  Þ0.5 =Þ0.5  
Iodine value   :  75–90, 75–85  
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Specific Properties: 
Melting point   :  13-14 °C (286 K) 
Flash point   :  175.3°C 
Freezing point  :  ˜×-×32°C  
Moisture content  :  0.08% (at 20°C and 52%RH) 
Surface tension  :  32.3 dynes/cm at 25°C  
Viscosity (dynamic)  :  3.9 cP at 25°C 
Viscosity (kinematic) :  4.6 cSt at 25°C  
 Pharmaceutical Application:     
 Oleic acid is used as an emulsifying agent in foods and topical 
pharmaceutical formulations. It has been used as a penetration enhancer in 
transdermal formulations, to improve the bioavailability of poorly water- 
soluble drugs in tablet formulations, and as part of a vehicle in soft gelatin 
capsules. 
 Oleic acid has been reported to act as an ileal ‘break’ that slows down the 
transit of luminal contents through the distal portion of the small bowel. 
 Oleic acid is used as a vehicle for certain parenteral preparations which are 
to be administrated by the intramuscular route 
 It has also been used as a solvent for drugs formulated as  biodegradable 
capsules for subdermal implantation and in the preparation of 
microemulsions  containing cyclosporine 
 Oleic acid labeled with 131I and 3H used in medical imaging 
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Safety : 
¾ Ethyl oleate is generally considered to be of low toxicity but ingestion 
should be avoided.  
¾ Ethyl oleate has been found to cause minimal tissue irritation. No reports 
of intramuscular  irritation during use have been recorded.  
Stability & Storage 
            Oleic acid should be stored in a cool, dry place in a small, well-filled, 
well-closed container, protected from light. 
 
  
5.2.2. Tween-2076 
 
Chemical Structure:  
 
w+x+y+z=20 
R=Fatty acids 
Synonyms   :  Armotan PML 20; Tween 20. 
Chemical Name  :  Polyoxyethylene 20 sorbitan    monolaurate 
Non-Proprietary Name :  Polysorbate 20 
Molecular formulae  :  C58H114O26. 
Molecular Weight  :  1128g/mol 
Functional Category  : Nonionic surfactant; suspending 
                                                              agent; wetting agent. 
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Description: 
Colour   :  Yellow oily liquid at 250C 
Odour and Taste  :  Polysorbates have a characteristic 
                                                             odor and a warm, bitter taste. 
Applications in Pharmaceutical Formulation or Technology: 
 Polysorbates containing 20 units of oxyethylene are hydrophilic 
nonionic surfactants that are used widely as emulsifying agents in 
the preparation of stable oil-in-water pharmaceutical emulsions.  
 Used as a solubilizing agents for a variety of substances including 
essential oils and oil-soluble vitamins, 
 Wetting agents in the formulation of oral and parenteral 
suspensions. 
Table 8: Pharmaceutical application of Tween-20 
 
Funtions Dosage form 
Concentration 
(%) 
 
 
 
 
Emulsifying 
agent 
 
O/W emulsions 1–15 
 
Combination with hydrophilic 
emulsifiers in O/W 
emulsions 
 
 
1-10 
Ointments 1-10 
Solubilizing 
agent 
Poorly soluble active constituents 
in lipophilic bases 
1-10 
Wetting agent 
 
Insoluble active constituents in 
lipophilic bases 
0.1-3 
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Typical properties: 
Acid value  :  2.0%  
Specific gravity :  1.1 at 25°C 
Viscosity   :  400 mPa s 
Surface tension :  34.7(mN/m) at 20°C  
Incompatibilities: 
Discoloration and/or precipitation occur with various substances, 
especially phenols, tannins, tars, and tarlike materials. 
Stability and Storage Conditions: 
 Polysorbates are stable to electrolytes and weak acids and bases; gradual 
saponification occurs with strong acids and bases. The oleic acid esters are 
sensitive to oxidation. 
 Polysorbates are hygroscopic and should be examined for water content 
prior to use and dried if necessary. Also, in common with other 
polyoxyethylene surfactants, prolonged storage can lead to the formation 
of peroxides. 
 Polysorbates should be stored in a well-closed container, protected from 
light, in a cool, dry. 
 
 
 
 
 
 
 
 
 
 DRUG AND EXCIPIENTS PROFILE   
 
   61 
 
5.2.2 Propylene Glycol77 
Chemical Structure:  
 
Molecular Formula : C3H5o2 
Synonyms : propylene glycol, α-propylene 
                                                               glycol, 1, 2-propanediol,  
Chemical Name : propane-1, 2-diol 
Nonproprietary Names (BP) : Propylene glycol 
Molecular Weight    : 76.09g/mol 
Funtional Category    : Antimicrobial preservative; 
                                                                           disinfectant; humectants 
Description     : 1.A clear and colorless  
        2. Viscous and practically odorless  
        3. Sweet, slightly acrid taste  
        4. Resembling glycerol    
Typical Properties: 
Boiling point : 188°C 
Flash point :  99°C 
Freezing point :  -59°C 
Surface tension :  40.1 dyne/ cm at 25°C 
Density     :  1.038 g/cm3 at 20°C 
Specific heat     :  2.47 J/g (0.590 cal/g) at 20°C 
Vapor density (relative)   :  2.62 (air = 1) 
Vapor pressure    :  9.33 Pa (0.07 mmHg) at 20°C 
Viscosity (dynamic)    :  58.1 mPa s (58.1 cP) at 20°C 
 DRUG AND EXCIPIENTS PROFILE   
 
   62 
 
Solubility: 
Miscible with acetone, chloroform, ethanol (95%), glycerin, and water; 
soluble at 1 in 6 parts of ether; not miscible with light mineral oil or fixed oils, but 
will dissolve some essential oils. 
 
Safety: 
Propylene glycol is used in a wide variety of pharmaceutical formulations 
and is generally regarded as a relatively nontoxic material. 
 
Stability and Storage Conditions: 
At cool temperatures, propylene glycol is stable in a well-closed container, 
but at high temperatures, in the open, it tends to oxidize, giving rise to products 
such as propionaldehyde, lactic acid, pyruvic acid, and acetic acid.  
 
Propylene glycol is chemicallystable when mixed with ethanol (95%), 
glycerin, or water; aqueous solutions may be sterilized by autoclaving. Propylene 
glycol is hygroscopic and should be stored in a well-closed container, protected 
from light, in a cool, dry place. 
 
Applications in pharmaceutical Formulation or Technology: 
 Propylene glycol has become widely used as a solvent, extractant, and 
preservative in a variety of parenteral and nonparenteral formulations. 
 It is a better general solvent than glycerin and dissolves a wide variety of 
meterials, such as corticosteroids, phenols, Sulfa drugs, barbiturates, 
Vitamins (A and D), most alkaloids, and many local anesthetics. 
 As an antiseptic it is similar to ethanol, and against molds it is similar to 
glycerin and only slightly less effective than ethanol. 
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Table 9: Pharmaceutical application of Propylene Glycol 
 
Funtion Dosage form Concentration (%) 
 
 
Solvent or 
co-solvent 
Oral solutions 10-25 
Parenterals 10-60 
Topical 
preparations 
 
5-80 
Aerosol solutions 10-30 
Humectant Topicals 15 
 
Preservative 
Solutions, 
semisolids 
15-30 
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6. MATERIALS AND EQUIPMENTS 
Table 10: List of Materials Used  
S.no 
 
Category Materials Manufacturer 
1 
 
Drug Lornoxicam 
Premier drug house, kandivali 
(west), Mumbai. 
2 
 
Oil Oleic acid Microfine chemicals,India 
3 
 
Oil Olive oil Scientific Chemicals, Chennai 
4 
 
Oil Castor oil 
Hi Pure Fine Chem Industries, 
Chennai. 
5 
 
Oil Isopropyl myristate 
Nice Chemicals Private Limited, 
Chennai 
6 
 
Oil Isopropyl palmitate 
Nice Chemicals Private Limited, 
Chennai 
7 
 
Surfactant Tween-20 Sigma aldrich chemie, Germany 
8 
 
Surfactant Span-20 Sigma aldrich chemie, Germany 
9 
 
Co- surfactant Propylene glycol 
Nice chemicals private limited, 
Chennai. 
10 
 
Co- surfactant Isopropyl alcohol 
Nice Chemicals Private Limited, 
Chennai 
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S.no 
 
Category Materials Manufacturer 
11 
 
Co- surfactant N-butanol Scientific Chemicals, Chennai 
12 
 
Reagent 
Potassium dihydrogen 
ortho phosphate 
Microfine chemicals, New Delhi. 
13 
 
Reagent Sodium hydroxide Microfine chemicals, New Delhi. 
14 
 
Reagent Hydrochloric acid Microfine chemicals, New delhi. 
15 
 
Reagent Methanol Ranken, India. 
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Table 11: List of Equipments Used 
S.no Equipments Manufacturer Use 
1 
UV-Visible double beam 
spectrophotometer 
Shimadzu UV 1700 
(Pharmaspec) 
To measure the 
absorbance of the sample 
2 Electronic Balance Sortorius Single Pan For weighing purpose 
3 Magnetic Stirrer 
Remi equipment, 
Mumbai. 
Microemulsions 
preparation 
4 pH meter Elico L 1120 
To measure the pH of the 
solution 
5 Brookfield Viscometer LVII model To measure the viscosity 
6 Cooling centrifuge Remi Phase separation study 
7 FTIR Perkin Elmer Compatibility study 
8 Optical microscope Nikon U.S 
To identify the 
formulations 
9 Digital camera 
Sony Cybershot, 12.1 
mega pixels 
For pictures 
10 Particle size Analyser 
Microtrac-Blue wave, 
U.S 
To measure the particle 
size 
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S.no Equipments Manufacturer Use 
11 AFM 
Commercial 
Nanoscope III Digital 
Instruments, Veeco, 
Surface morphology and 
the particle size 
12 TEM Topcon, Paramus, NJ Morphology and shape 
13 Digital plethysmometer 
Orchid scientifics, 
India. 
Anti-inflammatory 
activity 
14 Graph pad software Sandiego, CA 
Kinetics of drug release, 
Student’t-test 
15 
Environmental stability 
testing chamber 
Heco Environment 
Chamber 
For stability studies 
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 7. PREFORMULATION STUDIES 
Preformulation may be described as a stage of development process during 
which the researches characterize the physical, chemical and mechanical 
properties of the drug substance to form effective, stable and safe dosage form. 
Hence, preformulation studies are essential to characterize the drug for proper 
designing of the drug delivery system. The preformulation studies which were 
performing in this project include, 
 Description 
 Melting point 
 Solubility 
 Hygroscopic Nature 
 Identification of drug sample 
 Drug – excipient compatibility studies 
 
 7.1. Description 
Organoleptic characters of drug was observed and recorded by using 
descriptive terminology. 
 7.2. Melting point 
Capillary tube, which is sealed at one end is charged with sufficient 
amount of dry powder to form a column in the bottom of the tube 2.5mm to 
3.5mm, and packed down as closely as possible by moderate tapping on a solid 
surface. The apparatus is operated according to the standard operating procedure. 
The block is heated until the temperature is about 30o C below the expected 
melting point. The capillary tube is inserted into the heating block, and the heating 
is continued at a rate of temperature increased of about 1o C to 2o C per minute 
until melting is completed. 
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The temperature at which the detector signal first leaves its initial value is 
defined as the beginning of melting, and the temperature at which the detector 
signal reaches its final value is defined as the end of melting, or the melting point. 
The two temperatures fall within the limits of the melting range. 
 7.3. Solubility Studies 
The spontaneous interaction of two or more substance to form a 
homogenous molecular dispersion is called as solubility. 
10 mg of drug was a suspended separately in 10 ml of different solvents at 
room temperature in tightly closed tubes and shaken. The solubility profiles of 
two drugs in various solvents are shown in the table (12). 
Table 12:  Solubility Profile I.P. 1996 
Descriptive term 
Parts of solvent required for 1 
part of solute. 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly Soluble From 30 to 100 
Slightly Soluble From 100 to 1000 
Very slightly soluble From 1000 to 10, 000 
Practically insoluble of Insoluble Greater than or equal to 10,000 
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7.4. Hygroscopic Nature: 
7.4.1. Procedure 
 2 gm of the test specimens were weighed accurately in petridish and the 
weight were noted down. Then the test specimens were exposed to 75% RH at 
40°C in environment stability testing camber and the other was kept at room 
temperature for 7 days period. The specimen was weighed after 7 days and the 
difference in weight was noted down (Table 22). 
7.5. Identification of Drug Sample 
7.5.1. Finding the absorption maxima (λ max) 
The absorption maxima were found for drug identification. Ultraviolet 
visible spectrophotometry has been used to obtain specific information on the 
chromophoric part of the molecules. Organic molecules in solutions when 
exposed to light in the visible/ultraviolet region of the spectrum absorb light of 
particular wavelength on the type of electronic transition associated with the 
absorption. 
7.5.2. Preparation of Phosphate Buffer Solution [pH 7.4] I.P 1996 
¾ 27.218 g of potassium dihydrogen ortho phosphate was dissolved in 1000 
ml of distilled water to give a 0.2N solution 
¾ 8 g of sodium hydroxide was dissolved in 1000ml of distilled water to give 
0.2N solution 
¾ 1250ml of 0.2N potassium dihydrogen ortho phosphate and 977.5ml of 
0.2N sodium hydroxide were mixed together and made upto 5000ml with 
distilled water 
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The drug solution (10, 20, 30, 40, 50, 60 µg/ml) in Phosphate buffer pH 
7.4 was taken in standard cuvette, and scanned in the range of 200-300nm in a UV 
spectrophotometer. It exhibits maxima at 377nm. UV spectrum of drug taken in 
phosphate buffer pH 7.4 also exhibits maxima at 377nm. Therefore, further all 
measurements were taken at 377nm. The results are shown in fig 18.  
7.6. Standard curve 
7.6.1. Preparation of Standard plot for Lornoxicam in phosphate Buffer 
 pH 7.4 
 Accurately weighed amount of Lornoxicam (10 mg) was dissolved in 
small quantity of 0.1N sodium hydroxide and then diluted to 100 ml with 
phosphate buffer pH 7.4. Each ml of the stock solution contains 100µg of 
Lornoxicam. From this stock solution different standard of working standard 
solutions i.e., 10, 20, 30, 40, 50, 60 µg/ml were made up with phosphate buffer pH 
7.4 and the absorbance was measured at 377 nm using phosphate buffer pH 7.4 as 
blank by UV spectrophotometric method. A graph is plotted by using 
concentration at X-axis and absorbance at Y-axis. The values are given in the 
table: 25 and fig 19.   
7.7. Fourier transforms infrared (FTIR) spectral analysis 
 FTIR is used to identify the functional groups in the molecule. The drug is 
mixed with KBr disk was scanned at 4mm/s at a resolution of 2cm over a wave 
number region of 400 to 4000cm-1. The characteristic peaks were recorded. The 
results are shown in fig 20, 21, 22, 23, 24, 25 and table 26, 27, 28, 29, 30.     
7.8. Drug-Excipient Compatibility Studies by FT-IR Analysis 
Infrared spectrum of any compound or drug gives information about the 
groups present in that particular compound. The IR absorption spectra of the pure 
drug and physical admixtures of drug with various excipients were taken in the 
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range of 4000-400 cm-1 using KBr disc method (Schimadzu IR- Prestige-21) and 
observed for characteristic peaks of drug. 
Drug-Excipient compatibility was carried out by FT-IR analysis. Initially 
the IR spectrums of pure drug, Lornoxicam, Oleic acid, tween-20, propylene 
glycol were obtained. After that admixtures of drug with other excipients were 
prepared and IR Spectra was obtained. The obtained spectra of physical 
admixtures was observed for major peaks and recorded. The results of this 
observation were concluded that there is no interaction between the drug 
(Lornoxicam) and other excipients (Oleic acid, tween-20, propylene glycol). 
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8. FORMULATION DEVELOPMENT 
The pharmaceutical development studies have to be carried out with the 
purpose of selecting right dosage form and a stable formulation. These studies 
give detailed description of all the steps involved in the process of development of 
the finished procedure. Such details are intended towards identifying critical 
parameters involved in the process, which have to be controlled in order to give 
reliable and reproducible quality product. 
8.1. Dose calculation78 
 
 The total dose of drug, Dt in a prolonged action preparation comprises the 
normal (prompt) dose, Dn and the sustaining dose Ds i.e., Dt = Dn + Ds if the first 
order elimination rate constant is K, the rate at which drug is eliminated when a 
normal dose is given is Dn K which is the rate at which drug must be replaced if 
the peak blood level is to be maintained. Given a maintenance period‘t’ the 
maintenance dose (Ds) is Dn kt. The total dose is therefore: 
Dt = Dn+ Ds 
= Dn + DnKt 
= Dn (1+Kt) 
= Dn (1+0.693t/t1/2) 
Dt = Di (1+ 0.693 x tm/t1/2) 
Where, Dt = Total dose 
Di = initial dose 
tm = time to which the drug is sustained 
t1/2 = half life of the drug. 
Di= 10 mg 
t1/2 = 5 hrs 
tm = 24 hrs 
Dt = 10 (1 + 0.693 x 24/5) 
Dt= 35.26mg 
Dt = 35 mg (app) 
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 8.2. Calculation of HLB value for O/W type of Microemulsions79 
The HLB of a non-o-ionic surfactant whose only hydrophilic portion is 
polyoxyethylene is calculated by using the formula 
HLB= E/5 
Where, E is the percentage by weight of ethylene oxide. A number of 
polyhydric alcohol fatty acid esters, such as glyceryl monostearate, can be 
estimated the formula 
    HLB= 20(1-S/A) 
Where, S is the saponification number of the ester and A is the acid 
number of the fatty acid. The HLB of polyoxyethylene sorbitan monolaurate 
(tween-20),  
For which S=45.5 and A=276, is 
HLB= 20(1-45.5/276) =16.7 
The HLB values of some commonly used amphiphilic agents are given in table 
(13) 
The oil phase of an oil-in water (O/W) emulsion requires a specific HLB, 
called Required Hydrophile- Liphophile Balance (RHLB).A different RHLB is 
required to form water-in oil (W/O) emulsion from the same oil phase.The RHLB 
values for both O/W and W/O emulsions have been determined empirically for a 
number of oil and oil-like substances, some of which are listed in table (14). 
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Table 13: HLB Values of Some Amphiphilic Agents 
 
Substance HLB Value 
Oleic acid 1 
Span-80 4.3 
Span-20 8.6 
Brij-30 9.5 
Tween-80 15 
Tween-20 16.7 
Sodium oleate 18 
 
Table 14: RHLB for some oil phase ingredients for (O/W) and (W/O) 
emulsions 
    Oil   phase   
   ingredients 
 
O/W emulsion
 
W/O emulsion 
Cottonseed oil 6-7 - 
Mineral oil 10-12 5-6 
Castor oil 14 - 
Lauric acid 16 - 
Oleic acid 17 - 
8. 3. Selection of Oils 
 To find out the suitable oil, which can be used as oil phase in 
microemulsion, and provide excellent skin permeation rate of lornoxicam. The 
solubility of lornoxicam in various oils including olive oil, castor oil, isopropyl 
myristate, isopropyl palmitate, oleic acid was measured at 25°C. The solubility of 
olive oil, castor oil, isopropyl myristate, isopropyl palmitate, and oleic acid in oily 
mixtures was also measured48.  
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8.3. 1. Procedure: 
 About 10 gm of oil was accurately weighed in 25 ml glass beaker and 100 
mg of lornoxicam was added into it, followed by stirring on magnetic stirrer at 
moderate speed to dissolve the drug. When drug was dissolved completely another 
10 mg lornoxicam of was added and stirring was continued. Addition of drug was 
continued until the saturated solution is obtained. Finally, the total amount of drug 
consumed was determined by using UV-spectrophotometer at 377 nm. It was 
found that, oleic acid has consumed maximum amount of lornoxicam and thus 
chosen as a vehicle for microemulsion oil phase (15). 
Table 15: solubility of lornoxicam in various oils at 25o C 
 
S.no. 
Drug solubility 
(in mg/10 g of oil) 
 
Oils 
1 120 Olive oil 
2 150 Castor oil 
3 140 Isopropyl myristate 
4 120 Isopropyl palmitate 
5 180 Oleic acid 
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8.4. Selection of surfactants and co-surfactants48 
The non-ionic surfactants do not ionize at any great extent in the solution, 
they are greatly compatible with both anionic and cationic substances; various 
nonionic surfactants like, span 20, Tween-20 and co-surfactants like, propylene 
glycol, isopropyl alcohol and b-butanol  were subjected to titration. Finally, 
Tween-20 and propylene glycol were selected as an ideal surfactant and co-
surfactant for the system (Table 16). 
 
Table 16: Selection of surfactant and co-surfactants for optimization of 
formulations 
 
Surfactant: co-
surfactant 
 
 
Concentration 
ratio 
 
Appearance 
 
Tween-20: 
propylene glycol 
1:1 
 
2:1 
Clear 
Clear 
 
Tween-20: 
isopropyl alcohol 
1:1 
 
2:1 
Slightly cloudy 
Clear 
 
Tween-20: 
n-butanol 
1:1 
 
2:1 
Cloudy 
Clear 
 
Span-20:propylene 
glycol 
1:1 
 
2:1 
Clear 
Cloudy 
 
Span-20:isopropyl 
alcohol 
1:1 
 
2:1 
Slight cloudy 
Cloudy 
 
Span 20: n-butanol
1:1 
 
2:1 
Cloudy 
Cloudy 
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8.5. Preparation of Lornoxicam Microemulsions by Water Titration 
Method39 
O/w type of Microemulsion 
 
 
 
 
 
                                    
 
 
 
  
 
s 
 
 
 
 
 
 
 
 
 
 
Fig 17: Preparation of Lornoxicam Microemulsions 
O/W type of 
Micro emulsion 
Magnetic stirrer Magnetic stirrer 
Surfactant 
/Co-
Surfactant 
Continuous 
magnetic 
stirring 
Drop by 
drop 
added 
3000rpm 1hour 
at 24̊0C 
 
Drug +oil 
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8.6. Consideration for Formulation Development 
) Preparation of lornoxicam microemulsion trial formulation I and II by 
optimizing surfactant and co-surfactant ratios (1:1, 2:1) 
)  Optimization of  microemulsion formulation (Lornoxicam) by optimizing 
surfactant and co-surfactant is kept constant and oil amount was changed   
8.6.1. Trial Formulations  
 Different trial formulation were formulated and studied for their 
physicochemical characterization and visual observation. Finally get the 
optimized formulation. 
 The trial formulations of microemulsion were prepared based on following 
formula. Different percentage of surfactant and co-surfactant have been used in 
each trial formulation and studied to have controlled effect for period of 24 hours. 
Trial Batch-I: 
           The first trial formulations of lornoxicam microemulsion were prepared by 
employing drug and oil phase same concentration varying the percentage of 
surfactant and co-surfactant (Tween-20 and Propylene glycol, 1:1ratio).  It was 
shown in the table (17).     
Trial Batch-II: 
 In the second trial formulation, lornoxicam microemulsions were prepared 
by employing drug and oil phase same concentration and varying the percentage 
of surfactant and co-surfactant (Polysorbate-20 and Propylene glycol, 2:1ratio). It 
formulation was shown in the table (18). 
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Table 17: Formulation of trial batch I (F1-F5) 
Surfactant: co-surfactant (1:1) 
 
 
S.no 
 
 
 
Ingredients 
Formulations 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
1 Lornoxicam (mg) 10 10 10 10 10 
2 Oleic acid (%w/v) 2 2 2 2 2 
3 Tween-20 (%w/v) 1 2 3 4 5 
4 Propylene glycol 
(%w/v) 
1 2 3 4 5 
5 Distilled water (%w/v) 26 24 22 20 18 
6 Final volume (%w/v) 30 30 30 30 30 
 
Table 18: Formulation of trial batch II (F6-F10) 
Surfactant: co-surfactant (2:1) 
S.no 
 
 
Ingredients 
Formulations  
F6 F7 F8 F9 F10 
1 Lornoxicam (mg) 10 10 10 10 10 
2 Oleic acid (%w/v) 2 2 2 2 2 
3 Tween-20 (%w/v) 2 4 6 8 10 
4 Propylene glycol 
(%w/v) 
1 2 3 4 5 
5 Distilled water (%w/v) 25 22 19 16 13 
6 Final volume (%w/v) 30 30 30 30 30 
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Table 19: Compositions of the Selected Microemulsion Formulation 
 
 
S.no 
 
 
 
Formulations  
 
Lornoxicam
(mg) 
Oleic 
acid 
(%W/V)
 
Tween-
20 
(%W/V)
Propylene 
glycol 
(%W/V) 
Distilled 
water 
(%W/V) 
Final 
volume 
(%w/v)
1 ME-1 10 2 6 3 19 
 
30 
2 ME-2 10 4 
 
6 3 17 30 
3 ME-3 10 6 
 
6 3 15 30 
4 ME-4 10 8 
 
6 3 13 30 
5 ME-5 10 10 
 
6 3 11 30 
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9. CHARACTERIZATION OF MICROEMULSIONS 
9.1. Optical Transparency39  
Optical transparency of the formulation was determined by inspecting the 
sample in clear and transparent container under the presence of good light against 
reflection into the eyes, and viewed against black and white illuminated 
background.  
9.2. Determination of pH 
pH is measured using a pH meter of a glass electrode. pH fundamentally 
represents the value of hydrogen ion activity in solutions. It is defined by the 
equation given below. This value well accords with the logarithm of the reciprocal 
of hydrogen ion concentration in dilute solutions. 
     E－ＥS 
pH =  pHS ＋ 
     2.3026 RT／F 
Where, pHs = pH value of a pH standard solution, 
E = electromotive force (volt) on the combination of glass and reference 
       Electrodes in a sample solution; the constitution of the cell  
Es = electromotive force (volt) on the combination of glass and reference 
                    Electrodes in a pH standard solution, the constitution of the cell  
R = gas constant, 
T = absolute temperature, 
F = Faraday constant. 
The values of 2.3026 RT/F (volt) at various temperature of solutions. 
The pH was measured in microemulsion formulations using a ELICO 
LI120 pH meter that was calibrated before formulation use with buffered solutions 
at pH 4 and pH 9.2.  
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A defined amount of formulation was taken and diluted with calibrated 
distilled water and mixed well. The electrode of the pH meter was immersed in 
the prepared formulation for pH determination. 
About 2gm of formulation was dispersed into 20ml of distilled water and 
pH was determined by pH meter. 
9.3. Viscosity Measurements 
This procedure determines the viscosity of a fluid by the use of a Brookfield 
Viscometer. Viscosity is the measure of fluid friction which can be considered as the 
internal friction resulting when a layer of fluid is made to move in relationship to 
another layer. Viscosity is a measure of the ratio of shearing stress to rate of shear.  
    
    Shear Stress (dynes) 
                  = Poise 
    Rate of Shear (cm/sec) 
 
¾ Check to confirm that the viscometer has been calibrated. If not, calibrate 
using software. 
¾ The sample container and quantity should be approximately the same as for 
the Calibration Standard. Equilibrate the temperature of the sample to the 
temperature designated in the specification (±1°C). 
¾ Confirm that the viscometer is level using the bubble level on the back of the 
instrument. For the Brookfield LV-II, the instrument with spindle attached and 
the speed set as designated in the product specification. The main display will 
flash 00.0 after 10 seconds.  
¾ Immerse the spindle designated in the product specification into the sample to 
the groove on the spindle shaft. Do not allow air bubbles to be formed. Attach 
the spindle to the viscometer.  
¾ The spindle should not touch the bottom or sides of the container and should 
be centered. Reconfirm that the viscometer in level. 
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¾ The spindle no: 64 were rotated at a speed of 60 rpm. Samples of 
microemulsions were allowed to settle over 30 min at room temperature 
before the measurements were taken. 
¾ For the LV-II, choose the units by pressing the desired unit key (CPS for 
centipoises). 
¾ Set the speed as designated in the product specification, start the viscometer 
and read at constant reading. For manual models, use the conversion chart to 
convert the dial readings to centipoises. 
¾ When done, turn motor and power off. Clean spindle and place in spindle 
holder.  
9.4. Mechanical stress study30 
 The chemical and physical stability of microemulsion with lornoxicam 
were evaluated via phase separation by mechanical stress study. 
The different microemulsion formulations (ME-1 to ME-5) were 
centrifuged (Remi centrifuge) at 2000 rpm for different time interval (10min, 
30min, and 60min) and noted down the volume of phase separation of 
formulation. 
9.5. Particle shape and Surface Morphology 
9.5.1. Transmission Electron Microscopy (TEM) 
Morphology and structure of the microemulsion were studied using 
transmission electron microscopy with Topcon 002B operating at 200kv (Topcon, 
Paramus, NJ) and capable of point-to-point resolution. In order to perform 
transmission electron microscopy observations, a drop of the microemulsion was 
suitably diluted with water and applied on a carbon-coated grid, then treated with 
a drop of 2% phosphotungstic acid and left for 30s.The coated grid was dried 
under vacuum and then taken on a grid holder and observed under the 
transmission electron microscope. 
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9.5.2. Atomic Force Microscopy (AFM) 
 An atomic force microscope is an excellent for visualising particles with 
sizes ranging from 1 nm to 10 µm. Another advantage of the AFM is its simplicity 
of operation and that the AFM requires minimal sample preparation. Additionally, 
the AFM can operate in air, liquid or a vacuum. In comparison to traditional 
techniques for single particle analysis of sub-µm particles, the AFM gives three-
dimensional profiles. 
It is possible to make quantitative measurements of particle sizes with an 
AFM. It can easily measure particle sizing parameters as long as the particle is 
>100 nm. If the particle size is less than 100 nm special considerations must be 
taken into account.  
 
9.6. Particle Size Measurement 
9.6.1. Determination of particle size distribution by Particle size analyzer: 
 The selected best Lornoxicam microemulsion formulations were subjected 
to laser particle counting method. Here the sample was injected into the sample 
delivery and controlling chamber. Then, suitable solvent was pumped through the 
chamber. Now a beam of laser light was allowed to fall on the sample cell. After 
required number of runs, they were directed towards the detector. From this the 
particle size range and the average mean particle size of the formulation can be 
studied. The average particle size of Microemulsion formulations can be 
determined using particle size analyzer.  
9.7. Drug content analysis30 
1ml of Microemulsion Formulations was transferred into a beaker 
containing 10 ml methanol. The content of the beaker were stirred for 30 minutes 
and then kept for 24hr. After 24hr the content of beaker were transferred into 
centrifuge tube and centrifuged at the 3000 rpm for 10 min. Supernatant was 
separated and filtered. Then 0.1 ml of the supernatant was diluted appropriately 
with Phosphate Buffer Saline (PBS) pH 7.4 and assayed Spectrophotometrically 
for drug contant. 
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10.  IN VITRO SKIN PERMEATION STUDY,  
 
10.1. Preparation of Goat skin26: 
  Selected formulations were further studied for skin permeation using goat 
ear skin, obtained from the slaughter house after sacrificing the animal within 1 
hour. The average thickness of the goat skin was 0.28±0.06 mm and then the hair 
was removed from the upper portion of skin surface using an animal hair clipper, 
and, subsequently, full thickness of the skin was harvested. The fatty layer, 
adhering to the dermis side, was removed by surgical scalpel. Finally, these 
excised skins were thoroughly rinsed with distilled water and packed in aluminum 
foils. The skin samples were stored at -20°C and used within a week. 
 
10.1.1. In Vitro Skin Permeation Study 
 In-vitro permeation study of drug from ME-1 to ME-5 lornoxicam 
microemulsion formulations was carried out using Goat Skin. The average 
thickness of the skin was 0.28±0.06 mm. Skins were allowed to hydrate for 1 hour 
before being mounted on the open ended diffusion with the stratum corneum 
facing the donor compartment and the dermal side faced the receiver 
compartment.   
 
The receptor compartment was consist of 400mL of phosphate buffer (pH 
7.4) in 500 mL beaker and its temperature was maintained at 37 ±0.5°C and stirred 
at 300 rpm throughout the experiment. About 1gm of 1% lornoxicam 
microemulsion was placed in Goat Skin tied to the one end of open-ended glass 
cylinder that was then dipped into freshly prepared phosphate buffer on magnetic 
stirrer. Samples were taken from receptor mediums at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7 
and 8, 9, 10, 11, 12, 23, 24hrs and replaced immediately with an equal volume of 
fresh phosphate buffer equilibrated at 37 ±0.5°C. All the samples were analyzed 
for lornoxicam content at 377nm by UV-spectrophotometer. Cumulative amount 
of drug permeation was calculated from standard calibration curve. 
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Permeation Study:   
Apparatus : Open ended diffusion cylinder 
Speed  : 300rpm 
pH  : 7.4  
Time  : 1-24hrs 
Temperature : 37 C 
λmax  : 377nm 
10.2. Kinetics of drug release80, 81, 82 
Several theories and kinetic models describe the dissolution of drug from 
immediate release and modified release dosage forms. There are several models to 
represent the drug dissolution profiles where f (t) is a function of time related to 
the amount of drug dissolved from the pharmaceutical dosage form. 
 The quantitative interpretation of the values obtained in the dissolution 
assay is facilitated by the usage of a generic equation that mathematically 
translates the dissolution curve function of some parameters related with the 
pharmaceutical dosage forms. Drug dissolution from solid dosage forms has been 
described by kinetic models in which the dissolved amount of drug (Q) is a 
function of the test time‘t’ or Q(t). Some analytical definitions of the Q(t) function 
are commonly used, such as zero order, first order, Higuchi, Korsmeyer-Peppas, 
Hixson-Crowell models, Weibull models. These models are used to characterize 
drug dissolution/release profiles. 
10.2.1. (i) Zero Order Kinetics 
This model represents an ideal release profile in order to achieve the 
pharmacological prolonged action. Zero order release constitutes drug release 
from the dosage form that is independent of the amount of drug in the delivery 
system (that is, a constant release rate). The following equation is used to express 
the model: 
    Qt = Qo + Kot 
 
 
 
EVALUATION STUDIES 
    
88 
 
 
Where, Qt is the amount of drug dissolved in time t 
  Qo is the initial amount of drug in the solution 
  Ko is the zero order release constant 
For practical purposes the equation is rearranged: 
Percent drug released = Kt 
This is applicable to dosage forms like transdermal systems, coated dosage 
forms,     osmotic systems as well as matrix tablets with low soluble drugs. 
 
10.2.2. (ii) First Order Kinetics 
First order release constitutes drug release in a way that is proportional to 
the amount of drug remaining in its interior; in such a way that amount of drug 
released by unit time diminish. The following equation is used to express the 
model: 
log Qt = log Qo + Kt/2.303 
Where, Qt is the amount of drug dissolved in time t 
Qo is the initial amount of drug in the solution 
  K is the first order release constant 
For practical purposes the equation is rearranged: 
Log % of drug unreleased = Kt/2.303 
This model is applicable to dosage forms such as those containing water-
soluble drugs in porous matrices. 
 
10.2.3. (iii) Higuchi Model 
Higuchi describes drug release as a diffusion process based in Fick’s 
law,square root dependent. The following equation is used to express the model: 
Qt = Kht1/2 
Where, Qt is the amount of drug dissolved in time t 
Kh is the first order release constant 
For practical purposes the equation is rearranged: 
Percent drug released = Kt1/2 
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This model is applicable to systems with drug dispersed in uniform 
swellable polymer matrix as in case of matrix tablets with water soluble drugs. 
 
10.2.4(iv) Peppas-Korsmeyer Model 
This model is widely used when the release mechanism is not well known 
or when more than one type of release phenomenon could be involved 
The following equation is used to express the model 
Qt/Q∞ = Ktn 
Where, Qt is the amount of drug dissolved in time t 
Q∞ is the amount of drug dissolved in infinite time 
n is the release exponent indicative of drug release mechanism 
K is the kinetic constant 
For practical purposes the equation is rearranged: 
Log percent drug released = log k +n log t 
 
Peppas used n value in order to characterize different release mechanism 
concluding for values of n = 0.5 for Fickian diffusion and values of n, between 0.5 
to 1.0 for anomalous transport (corresponds to diffusion, erosion and swelling 
mechanism or mixed order kinetics) and higher values of n, n=1 or n>1 for case-II 
transport (corresponds to erosion and relaxation of swollen polymer layer). 
10.3. In-vivo study design63 
10.3.1. Anti-inflammatory activity:   
Materials and methods: 
Chemicals:  
♣ Carrageenan, type I, Sigma‐Aldrich Louis, MO, (USA);   
♣ Lornoxicam microemulsion(ME-3) formulation as prepared in our lab. at 
department of Pharmaceutics. 
The anti-inflammatory and sustaining action of the optimized formulation 
(ME-3) was evaluated by the carrageenan-induced hind paw edema method 
developed by Winter et al in Wistar rats. 
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Animals: 
  White male albino rats weighting between (170gm and 200 gm) were 
selected for evaluation of the anti‐inflammatory activity by measurement of 
oedema size resulting from carrageenan injection in the right hind paw region of 
the body. The animals were kept under standard laboratory conditions with free 
access to a standard laboratory diet and water ad libitum. The dose for the rats was 
calculated based on the weight of the rats according to the surface area ratio.  
Treatment: 
The animals were divided into two groups, consisting of (six animals per 
each). 
Group 1:‐ Control group treated with non medicated microemulsion. 
Group 2:‐ Treated group with Lornoxicam‐ microemulsion 
 
 
Paw oedema size induced by carrageenan injection: 
 Certain amount of the investigated microemulsion (100 mg) was applied 
topically to the right hind paw of the rats.  The area of application is lightly 
occluded with bandages and it was left in place for two hours. The dressing was 
then removed and the microemulsion remaining on the surface of the skin was 
wiped off with a piece of cotton. 
 
 The paw volume was determined immediately before carrageenan 
injection and considered as zero time. The animals were then injected with 0.1 ml 
of 1% freshly prepared sterile carrageenan solution in saline into sub‐plantar 
region of right hind paw of rats. 
 
 The contralateral paw received an equal volume of saline. The right hind 
paw thickness was measured from ventral to dorsal surfaces, with a dial caliper, 
after 0.5, 1, 2, and 3 hrs after the sub‐plantar injection of carrageenan.  
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The size of oedema which expressed as a percentage change in paw 
thickness (in mm) from control (pre‐drug, zero time) and measured by digital 
plethysmometer fig: 59.  The experimental setup has shown in Fig 60. The amount 
of paw swelling was determined for 3 hours and expressed as percent oedema 
relative to the initial hind paw volume. The percent inhibition of edema produced 
by each formulation-treated group was calculated against the respective control 
group. 
 
10.4. Statistical analysis: 
It was carried out by Student’ t‐test using Excel by Graph pad software, to 
determine the significance of the obtained results between the prepared 
lornoxicam microemulsion. 
The % of the effect (inhibition) was calculated by the following 
Equation: = [(Control – drug)/ control] x 100. 
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11. STABILITY STUDY 
 Nowadays, stability testing has become an integral part of formulation 
development. It generates information on which proposal the shelf life of drug or 
dosage form and their recommended storage conditions are based. 
11.1. Accelerated stability studies 
Definition: 
 Stability of a pharmaceutical preparation can be defined as the capability 
of a particular formulation (dosage form or drug product) in a specific container 
/closure system to remain within its physical, chemical, microbiological, 
therapeutic and toxicological specifications throughout its shelf- life. 
Purpose of stability testing: 
♫ To study of drug decomposition kinetics 
♫ To develop stable dosage form 
♫ To establish the shelf- life or expiration date for commercially available 
drug product 
♫ To ensure the efficacy, safety and quality of active drug substances and 
dosage forms 
ICH Guidelines – Specifications83 
 5% potency loss from initial assay of batch 
 Any specified degradation that exceed specifications 
 Product failing out of pharmacopoeial limits. 
 Dissolution out of specification for 12 minutes. 
 Failure to meet specification for appearance and physical properties. 
Any one condition is observed then stability of the batch is failed. 
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Table 20: Stability Storage Conditions84, 85 
 
S.No. Study Period 
Storage 
Condition 
Minimum 
Duration 
1 Longer 
25 + 2o C 60 
+ 5% RH 
6 Months 
2 Intermediate 
30 + 2 o C 65 
+ 5% RH 
3 Months 
3 Accelerated 
40 + 2o C 75 
+ 5% RH 
3 Months 
 
 Stability of microemulsion formulations on storage is of a great concern as 
it is the major problem in the development of marketed preparation. Selected 
microemulsion formulations (ME-3) were placed in a high density polyethylene 
container and kept in stability chamber maintained at 40°c and 75% RH. The 
stability studies were carried out for a period of three months. The microemulsion 
formulation were tested and checked at regular intervals for changes in percentage 
of drug content. The results are discussed in table20. 
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12. RESULTS AND DISCUSSION 
12.1. Preformulation studies 
Description: 
Nature  :  Yellow crystalline powder 
Taste   :  weakly acidic drug 
Melting point: 
Table 21: Melting Point Determination 
Drug *Melting point (°) Normal range (°) 
Lornoxicam 240 ± 0.145 239-241 
 
* All values are expressed as Mean ± S.D, n=3. 
Solubility: 
The solubility of drug in various solvents was shown in the table 
Table 22: Solubility Profile of Lornoxicam 
S. No Solvent Solubility 
1. Distilled water Slightly Soluble 
2. Phosphate buffer (pH 7.4) Very Soluble 
3. Methanol Very Soluble 
4. Ethanol Slightly Soluble 
5. Chloroform Slightly soluble 
6. 0.1N  NaoH Very soluble 
 
 RESULTS AND DISCUSSION  
 
   95 
 
Hygroscopic Nature: 
                                 Table 23: Hygroscopic Nature of LX 
 
At Room Temperature 75% RH at 40° 
Sample No-1 Sample No-1 
Weight Gain Observed-
Nil 
Weight Gain 
Observed-Nil 
 
                             Lornoxicam is non hygroscopic in Nature 
 
                                   12.2. Identification of Drug Sample 
 
          Fig 18: UV spectrum of Lornoxicam in phosphate buffer pH 7.4 
 
 
 RESULTS AND DISCUSSION  
 
   96 
 
               Table 24: Absorption maxima of Lornoxicam in phosphate buffer pH 7.4 
 
Solvent 
 
Concentration 
(µg)/ml 
[[[[[
λ max 
(nm) 
[
Absorbance 
Phosphate 
buffer 
pH 7.4 
 
60 
 
377 
 
0.6702 
 
Standard plot of Lornoxicam in phosphate buffer pH 7.4 
Table 25: UV Absorbance of phosphate buffer pH 7.4 
S.No. Concentration (µg/ml) Absorbance at 377nm 
1 10 0.1219 
2 20 0.2151 
3 30 0.3413 
4 40 0.4568 
5 50 0.5615 
6 60 0.6702 
 
sa = 0.002 
b = 0.011 
r = 0.999 
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FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: S N-1.sp 
Date: 1/7/2012
S N-1.pk
SN-1~1.SP  1801  4000.00  400.00  4.04  97.30  4.00  %T  10  0.50
REF 4000 95.75 2000 69.48 600
3930.10  93.08  3793.09  87.82  3701.57  86.87  3400.78  47.79  3060.12  34.88  
2870.86  43.54  2758.92  43.61  2360.77  50.92  1596.16  4.99   1538.68  4.04   
1420.63  6.46   1379.47  7.32   1327.42  5.67   1238.55  24.04  1151.41  7.91   
1083.58  19.92  1033.58  15.34  829.27   30.36  787.38   27.01  624.77   57.32  
577.43   73.82  542.01   67.33  499.86   75.90  451.05   78.18  
4000.0 3000 2000 1500 1000 400.0
0.0
10
20
30
40
50
60
70
80
90
100.0
cm-1
%T 
3930.10
3793.09
3701.57
3400.78
3060.12
2870.86
2758.92
2360.77
1596.16
1538.68
1420.63
1379.47
1327.42
1238.55
1151.41
1083.58
1033.58
829.27
787.38
624.77
577.43
542.01
499.86
451.05
Fig 19:  Standard plot of Lornoxicam in pH 7.4 
 
The Standard plot has good regression coefficient and it shows the linearity. 
12.3. FTIR 
Fig 20: FT-IR of Lornoxicam 
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Table 26: FT-IR Spectral assignment of Lornoxicam 
Wavenumber in  (cm-1) Functional groups 
3400.78 O-H stretching 
3060.12 N-H stretching 
2870.86,2758.92 C-H(Aromatic) stretching 
1596.16            Carbonyl –C=O stretching 
1538.68 NH(Amide) stretching 
1420.63 S=O stretching 
1379.47 C-S Stretching 
1238.55 C-O Stretching 
1151.41 C-N Stretching 
829.27,624.77,451.05 C-H outplane bending 
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FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: S N-2.sp 
Date: 1/7/2012
S N-2.pk
SN-2~1.SP  1801  4000.00  400.00  3.31  99.35  4.00  %T  10  0.50
REF 4000 98.32 2000 65.04 600
3931.69  94.63  3803.69  91.53  2924.94  3.31   2671.26  19.17  2037.49  64.39  
1715.82  6.68   1444.79  12.19  1277.61  13.16  945.23   22.40  721.75   32.32  
487.46   69.67  
4000.0 3000 2000 1500 1000 400.0
0.0
10
20
30
40
50
60
70
80
90
100.0
cm-1
%T 
3931.69
3803.69
2924.94
2671.26
2037.49
1715.82
1444.79
1277.61
945.23
721.75
487.46
 
Fig 21:  FT- IR of oleic acid 
 
Table 27: FT-IR spectral assignment of Oleic acid 
Wavenumber in (cm-1) Funtional groups 
2924.94 C-H Stretching 
1715.82 C-O Stretching 
1277.61 C-O Stretching 
721.75 C-H Out of plane bending 
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Fig  22:  FT-IR of  Tween-20 
FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: S N-3.sp 
Date: 1/7/2012
S N-3.pk
SN-3~1.SP  1801  4000.00  400.00  3.17  99.99  4.00  %T  10  0.50
REF 4000 67.89 2000 63.43 600
3926.07  65.07  3793.76  62.87  3389.55  3.17   2932.48  6.49   2359.33  48.52  
2177.72  56.07  1652.81  22.01  1413.56  16.61  1132.93  19.52  1047.06  15.93  
996.03   33.06  929.45   28.91  837.76   35.28  664.32   32.37  
4000.0 3000 2000 1500 1000 400.0
0.0
10
20
30
40
50
60
70
80
90
100.0
cm-1
%T 
3926.07
3793.76
3389.55
2932.48
2359.33
2177.72
1652.81
1413.56
1132.93
1047.06
996.03
929.45
837.76
664.32
 
 
Table 28: FT-IR spectral assignment of Tween-20 
 
Wavenumber in (cm-1) Funtional groups 
3389.55 N-H Stretching in Primary amine 
2932.48 C-H Stretching 
837.76 C-O Stretching 
664.32 C-H Out of plane bending 
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FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: S N-4.sp 
Date: 1/7/2012
S N-4.pk
SN-4~1.SP  1801  4000.00  400.00  3.28  99.42  4.00  %T  10  0.50
REF 4000 96.65 2000 64.66 600
3928.62  91.17  3812.42  90.39  3409.33  3.77   2917.08  3.49   2346.22  79.43  
2140.47  70.24  1963.02  57.33  1733.07  14.93  1643.55  23.24  1458.51  12.57  
1353.74  12.92  1293.57  13.61  1251.70  13.12  1107.72  3.28   944.82   18.49  
851.64   28.60  557.07   39.39  
4000.0 3000 2000 1500 1000 400.0
0.0
10
20
30
40
50
60
70
80
90
100.0
cm-1
%T 
3928.62
3812.42
3409.33 2917.08
2346.22
2140.47
1963.02
1733.07
1643.55
1458.51
1353.74
1293.57
1251.70
1107.72
944.82
851.64
557.07
Fig 23: FT-IR of Propylene glycol 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 29:  FT-IR spectral assignment of Propylene glycol 
 
Wavenumber in (cm-1) Funtional groups 
3409.62 O-H Stretching 
2917.08 C-H Stretching 
1251.70 C-O Stretching 
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FTIR SPECTRUM
ACIC
St.Joseph's  College ( Autonomous )
Trichy-2
Spectrum Name: S N-5.sp 
Date: 1/7/2012
S N-5.pk
SN-5~1.SP  1801  4000.00  400.00  3.38  98.59  4.00  %T  10  0.50
REF 4000 97.67 2000 81.94 600
3928.79  96.71  3794.15  93.35  3388.82  12.37  3059.72  15.55  2923.23  4.98   
1975.96  81.31  1722.10  14.65  1640.97  12.39  1598.92  13.63  1537.81  13.57  
1421.57  4.80   1377.32  5.21   1327.64  4.55   1242.68  9.02   1141.05  3.38   
1041.83  7.01   947.20   15.82  836.67   24.20  789.31   33.47  726.94   39.45  
622.10   46.72  541.67   53.15  454.45   74.52  
4000.0 3000 2000 1500 1000 400.0
0.0
10
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30
40
50
60
70
80
90
100.0
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%T 
3928.79
3794.15
3388.82
3059.72
2923.23
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1722.10
1640.97
1598.92
1537.81
1421.57
1377.32
1327.64
1242.68
1141.05
1041.83
947.20
836.67
789.31
726.94
622.10
541.67
454.45
Fig 24:  FT-IR of physical  Admixture 1.  (Lornoxicam + Oleic acid + 
Tween-20 + Propylene glycol) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 30: FT-IR spectral assignments Physical admixtures-1, 
 Lornoxicam + Oleic acid + Tween-20 + Propylene glycol 
Wavenumber in (cm-1) Assignment 
3388.82 O-H Stretching 
3059.72, 2923.23 C-H Stretching 
1722.10 C=O Stretching 
 
1598.92 C-N Stretching 
1327.64 N=O Stretching 
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There are no extra peaks seen other than the normal peak in the spectra of 
the mixture of the drug and excipients and so there is no interaction with the drug 
and excipient and they are compatible with each other. 
The IR spectra of the drug and polymer combination were compared with 
the spectra of the pure drug and individual excipients in which no shifting of 
peaks was significantly found, indicating the stability of the drug during 
microemulsion formulation development. 
 
12.2. Characterization of Microemulsions 
 
12.2.1. Optical transparency 
      Table 31: Appearance of Formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation 
 
Appearance 
ME-1 
 
Milky 
 
ME-2 Opalescent 
 
ME-3 Clear 
 
ME-4 Milky 
 
ME-5 Milky 
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Fig 25: ME-1 
 
 
 
 
 Fig 26: ME-2 
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Fig 27: ME-3 
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 Fig 28: ME-4 
 
 
 
 Fig 29: ME-5 
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pH determination 
                     Table 32:  Comparative pH values of Formulations 
 
 
 
 
 
 
 
 
 
 
*Values are mean ±SD, n=3 
 
         Fig 30:  Comparative pH values of Formulations 
 
 
 
Formulations 
 
pH* 
MEI 6.12±0.04 
 
ME2 5.75±0.03 
 
ME3 6.42±0.02 
 
ME4 5.81±0.03 
 
ME5 4.35±0.06 
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Viscosity measurements 
              Table 33:  Comparative Viscosity values of Formulations 
 
 
 
 
 
 
 
 
 
 
*Values are mean ±SD, n=3 
 
 
                 Fig 31:  Comparative Viscosity values of Formulations 
 
 
 
 
 
Formulations 
 
Viscosity(cps)* 
ME-1 52.6±0.6 
ME-2 75.3±0.8 
ME-3 91.4±0.4 
ME-4 103.5±0.5 
ME-5 118.2±0.2 
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Mechanical stress study 
 
Table 34: Comparative studty of mechanical stress in Formulations 
 
S.No Centrifugation 
time ( min) 
% Phase separation 
 
 
 
 
 
 
 
 
 
 
 
 
 
ME-1 ME-2 ME-3 ME-4 ME-5 
1 10 - - -  
- 
2 
2 30 
 
4 - - 8 6 
3 60 8 2 - 12 10 
 
 
 
       Fig 32: Comparative studty of mechanical stress in Formulations 
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  TEM PHOTOGRAPH OF FORMULATION (ME-3) 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig: 33 
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              AFM PHOTOGRAPH OF FORMULATION (ME-3) 
 
Fig (a) 34:  particle size range of Formulation (ME-3) 
 
 
 
 
 
Fig (b) 35:  particle size range of (ME-3) 
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Determination of particle size 
 
  
 
 
 
Fig 36: Particle size Measurement of ME-3 
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Drug content: 
 
     Table 35: Comparative drug content of Formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          *Values are mean ±SD, n=3 
 
 
 
Fig 37: Comparative drug content of Microemulsion formulations 
 
 
0
50
100
150
ME-1
ME-2
ME-3
ME-4
ME-5
Formulations
D
ru
g 
co
nt
en
t (
%
)
 
 
 
 
Formulations 
 
Drug content (%)* 
ME-1 82.42±0.32 
ME-2 93.12±0.54 
ME-3 98.54±0.26 
ME-4 90.21±0.42 
ME-5 86.34±0.28 
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ME-3 Formulation possesses higher drug content compared to other ME 
formulations. 
 
Table 36: Comparative in vitro Skin permeation rate  of Lornoxicam 
Microemulsions 
 
Time in 
hours 
 
Cumulative % drug permeated (µg/cm2)* 
ME-1 ME-2 ME-3 ME-4 ME-5 
0  0  0 0 0 0 
0.5  3.71±0.12  7.06±0.032  6.59±0.42  4.22±0.12  10.70±1.02 
1  4.32±0.02  11.03±0.42  14.56±0.31 10.02±0.02 14.70±0.34 
2  5.84±2.11  13.15±2.12 18.59±2.10 17.23±0.31 19.39±0.15 
4  8.76±0.21  16.22±1.25  27.96±0.24 21.98±1.02 20.79±0.52 
6  10.09±1.13 18.52±0.02 33.12±0.15 25.44±1.32 25.41±0.12 
8  15.14±0.02  20.25±1.01  41.24±1.02 29.05±2.01 28.36±0.32 
10  18.02±0.21  24.65±0.21  47.14±0.21 32.72±0.02 31.14±2.53 
12  21.80±1.04  27.53±1.31 53.98±2.25 35.68±0.12 33.80±1.28 
14  25.44±0.01  29.73±0.20  61.19±0.20 43.53±0.21 36.22±0.28 
16  27.96±0.02  33.77±0.35 67.24±1.01 50.34±1.20 44.61±0.2 
18  32.76±2.24  42.23±2.25  75.68±0.13 57.30±2.03 49.66±1.26 
20  35.57±0.31  49.62±0.14  83.24±0.20 66.56±0.41 57.80±0,02 
22  43.53±0.24  59.03±0.21 86.12±2.02 70.92±0.25 64.76±1.25 
24  50.63±0.02  66.56±2.32  88.79±0.15 78.13±1.02 76.40±0.15 
 
 
*Values are mean ±SD, n=3 
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Fig 38: Comparative in vitro Skin permeation rate  of Lornoxicam 
Microemulsions 
 
 
 
 
 
The comparative graph indicates ME-3 had higher skin permeation rate 
compared other microemulsion formulations. 
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Table 37: Model fitting of the in vitro Permeation data of various 
 lornoxicam microemulsions 
 
[[ 
 
[[ 
 
 
Formulations 
 
          r2  value 
Zero 
order 
First 
order 
Higuchi Korsmeyer-
peppas 
Diffusional 
exponent 
(n) 
ME-1 0.978 0.817 0.899 0.999 0.7 
 
ME-2 0.941 0.817 0.845 0.563 1.9 
 
ME-3 0.989 0.958 0.981 0.988 1.0 
 
ME-4 0.982 0.817 0.933 0.644 2.0 
 
ME-5 0.955 0.817 0.873 0.913 1.1 
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Release kinetics: 
 
 
Table 38: Release kinetics of ME-1 
 
 
 
Time 
in 
hrs 
Log 
Time 
√Time % 
Cumulative 
drug release 
Log Cumu. %  
Drug Release 
log %Cumu. 
of drug 
remaind 
0.50 0.3010 0.71 3.711712 0.5696 1.9836 
1.00 0.0000 1.00 4.324324 0.6359 1.9808 
2.00 0.3010 1.41 5.837838 0.7663 1.9739 
4.00 0.6021 2.00 8.756757 0.9423 1.9602 
6.00 0.7782 2.45 10.09009 1.0039 1.9538 
8.00 0.9031 2.83 15.13514 1.1800 1.9287 
10.00 1.0000 3.16 18.01802 1.2557 1.9137 
12.00 1.0792 3.46 21.8018 1.3385 1.8932 
14.00 1.1461 3.74 25.44144 1.4055 1.8725 
16.00 1.2041 4.00 27.96396 1.4466 1.8575 
18.00 1.2553 4.24 32.75676 1.5153 1.8276 
20.00 1.3010 4.47 35.56757 1.5511 1.8091 
22.00 1.3424 4.69 43.53153 1.6388 1.7518 
24.00 1.3802 4.90 50.63063 1.7044 1.6935 
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Fig 39: ME-1 Zero order plot 
 
 
 
 
 
 
Fig 40: ME-1 First order plot 
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Fig 41: ME-1 Higuchi plot 
 
 
 
 
 
 
Fig42 :  ME-1Korsemeuer-peppas model 
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Table 39: Release kinetics of ME-2 
 
 
Time 
in hrs 
Log 
Time 
√Time % 
Cumulative 
drug 
release 
Log Cumu. 
%  Drug 
Release 
log %Cumu. of 
drug remaind 
0.50 -0.3010 0.71 7.063063 0.8490 1.9682 
1.00 0.0000 1.00 11.02703 1.0425 1.9493 
2.00 0.3010 1.41 13.15315 1.1190 1.9388 
4.00 0.6021 2.00 16.21622 1.2099 1.9232 
6.00 0.7782 2.45 18.52252 1.2677 1.9110 
8.00 0.9031 2.83 20.25225 1.3065 1.9017 
10.00 1.0000 3.16 24.64865 1.3918 1.8771 
12.00 1.0792 3.46 27.53153 1.4398 1.8601 
14.00 1.1461 3.74 29.72973 1.4732 1.8468 
16.00 1.2041 4.00 33.76577 1.5285 1.8211 
18.00 1.2553 4.24 42.23423 1.6257 1.7617 
20.00 1.3010 4.47 49.62162 1.6957 1.7022 
22.00 1.3424 4.69 59.02703 1.7711 1.6125 
24.00 1.3802 4.90 66.55856 1.8232 1.5243 
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Fig43 : ME-2 Zero order plot 
 
 
 
 
 
 
Fig 44: ME-2 First order plot 
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Fig 45: ME-2 Higuchi plot 
 
 
 
 
 
Fig 46: ME-2 Korsemeuer-peppas model 
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Table 40: Release kinetics of ME-3 
 
 
 
Time 
in 
hrs 
Log 
Time 
√Time % 
Cumulative 
drug release
Log 
Cumu. %  
Drug 
Release 
log %Cumu. 
of drug 
remaind 
0.50  0.3010  0.71  6.59 0.8189  1.9704 
1.00  0.0000  1.00  14.55 1.1629  1.9317 
2.00  0.3010  1.41  18.59  1.2693  1.9107 
4.00  0.6021  2.00  27.96  1.4465  1.8576 
6.00  0.7782  2.45  33.11  1.5200  1.8254 
8.00  0.9031  2.83  41.24  1.6153  1.7691 
10.00  1.0000  3.16  47.13  1.6733  1.7232 
12.00  1.0792  3.46  53.98 1.7322  1.6629 
14.00  1.1461  3.74  61.18  1.7866  1.5891 
16.00  1.2041  4.00  67.24  1.8276  1.5153 
18.00  1.2553  4.24  75.67  1.8789  1.3861 
20.00  1.3010  4.47  83.24  1.9203  1.2243 
22.00  1.3424  4.69  86.12  1.9351  1.1424 
24.00  1.3802  4.90  88.79 1.9484  1.0496 
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Fig 47: ME-3 Zero order plot 
 
 
 
 
 
 
 
Fig 48: ME-3 First order plot 
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Fig 49: ME-3 Higuchi plot 
 
 
 
 
 
Fig 50:  ME-3 Korsemeuer-peppas model 
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  Table 41: Release kinetics of ME-4 
 
 
 
Time 
in 
hrs 
Log 
Time 
√Time % 
Cumulative 
drug release
Log 
Cumu. %  
Drug 
Release 
log %Cumu. 
of drug 
remaind 
0.50  ‐0.3010  0.71 4.216216 0.6249 1.9813 
1.00  0.0000  1.00  10.01802  1.0008  1.9542 
2.00  0.3010  1.41  17.22523  1.2362  1.9179 
4.00  0.6021  2.00  21.98198  1.3421  1.8922 
6.00  0.7782  2.45  25.44144  1.4055  1.8725 
8.00  0.9031  2.83 29.04505 1.4631 1.8510 
10.00  1.0000  3.16  32.72072  1.5148  1.8279 
12.00  1.0792  3.46  35.67568  1.5524  1.8084 
14.00  1.1461  3.74 43.53153 1.6388 1.7518 
16.00  1.2041  4.00  50.34234  1.7019  1.6960 
18.00  1.2553  4.24  57.2973  1.7581  1.6305 
20.00  1.3010  4.47 66.55856 1.8232 1.5243 
22.00  1.3424  4.69  70.91892  1.8508  1.4636 
24.00  1.3802  4.90  78.12613  1.8928  1.3399 
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Fig 51: ME-4 Zero order plot 
 
 
 
 
 
 
Fig52 : ME-4 First order plot 
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Fig 53: ME-4 Higuchi plot 
 
 
 
 
 
Fig 55: ME-4 Korsemeuer-peppas model 
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Table 42: Release kinetics of ME-5 
 
 
 
Time 
in 
hrs 
Log 
Time 
√Time % 
Cumulative 
drug 
release 
Log Cumu. 
%  Drug 
Release 
log 
%Cumu. of 
drug 
remaind 
0.50  ‐0.3010  0.71 10.7027 1.0295 1.9508 
1.00  0.0000  1.00  14.7027  1.1674  1.9309 
2.00  0.3010  1.41  19.38739  1.2875  1.9064 
4.00  0.6021  2.00  20.79279  1.3179  1.8988 
6.00  0.7782  2.45  25.40541  1.4049  1.8727 
8.00  0.9031  2.83 28.36036 1.4527 1.8552 
10.00  1.0000  3.16  31.13514  1.4933  1.8380 
12.00  1.0792  3.46  33.8018  1.5289  1.8208 
14.00  1.1461  3.74 36.21622 1.5589 1.8047 
16.00  1.2041  4.00  44.61261  1.6495  1.7434 
18.00  1.2553  4.24  49.65766  1.6960  1.7019 
20.00  1.3010  4.47 57.8018 1.7619 1.6253 
22.00  1.3424  4.69  64.75676  1.8113  1.5471 
24.00  1.3802  4.90  76.3964  1.8831  1.3730 
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Fig 55: ME-5 Zero order plot 
 
 
 
 
Fig 56: ME-5 First order plot 
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Fig 57: ME-5 Higuchi plot 
 
 
 
 
 
Fig 58:  ME-5 Korsemeuer-peppas model 
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In vivo Study 
 
Anti-inflammatory activity of ME-3 
 
 
 
 
 
 
Fig 59: Digital plethysmometer 
 
 
 
 
 
Fig 60: Testing of Wistar rat 
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Fig 61: Before treatment of ME-3 Formulation 
 
 
 
 
 
Fig 62: After treatment of ME-3 Formulation 
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Table 43: Anti inflammatory activity of Lornoxicam against Carragenin 
induced Paw Edema in Wistar Rats 
 
 
Treatment 
% increase in paw volume mean ± S.D (n=3)  
% inhibition 
in paw 
volume 
Post insult time of assay in minutes 
0 60 120 180 
Control 
(0.5 ml/kg) 
30.91 
± 
1.53 
69.32 
± 
3.12 
97.83 
± 
8.13 
108.59 
± 
9.09 
 
-- 
Lornoxicam 
Microemulsion 
ME-3 
(10 mg/Kg) 
29.74 
± 
1.58 
46.64*** 
± 
3.3 
75.8*** 
± 
5.3 
64.42*** 
± 
3.91 
 
40.67 
Standard- 
Indomethacin 
(10 mg/kg) 
28.46 
± 
0.92 
33.8 
± 
1.83 
38.8 
± 
2.32 
43.2 
± 
3.21 
 
60.21 
 
 
Data presented are Mean ±SD 
p-value *<0.01; **<0.001; ***<0.0001 Vs Control group using paired ‘t” test 
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Fig 63: % of Increase in Paw volume 
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Fig 63:  presented are Mean ±SD 
P-value *<0.01; **<0.001; ***<0.0001 Vs Control group using paired ‘t” test 
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Stability Study: 
 
S.No Formulation 
 
ME-3 
Before storage Stored at 40°C ± 2°C and 75%±5% RH 
 
1st month 2nd month 3rd month 
1 
 
Drug content 
(%) 
98.54 98.23 98.01 97.36 
2 pH 6.42 
 
6.31 6.01 5.65 
3 Viscosity(cps) 91.4 
 
90.2 90 90 
 
Fig 44: Stability study 
Discussion: 
 
 
 Transdermal drug delivery systems facilitate the passage of therapeutic 
quantities of drug substances through the skin and into the general circulation for 
their systemic effects. Topical administration of drugs with systemic effect can 
have advantages over other methods for several reasons, one of which is the 
avoidance of hepatic first-pass metabolism of the drug and related toxicity effects, 
controlling the rate of delivery and modulating distribution of drug in the systemic 
circulation.  In developing a transdermal delivery system, two criteria are 
considered: one is achieving adequate flux across the skin and the other is 
minimizing the lag time in skin permeation. 
 Transdermal delivery of microemulsion system, which composed of 
non-irritating, pharmaceutically acceptable ingredients. Microemulsion was 
prepared by water titration method using oleic acid as oil phase, tween-20 as 
surfactant and propylene glycol as co-surfactant  
 Different oils, surfactants and co-surfactants were screened to select ideal 
components of microemulsions with good solubility and excellent skin penetration 
of lornoxicam. The solubility of lornoxicam was highest in oleic acid followed by 
olive oil, castor oil, and isopropyl myristate, isopropyl palmitate.  
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The use of Oleic Acid is advantageous because it increase skin 
permeability by two mechanistic scenarios of the enhancer; (a) lipid fluidization, 
and (b) lipid phase separation, oleic acid is a model skin permeation enhancer, 
Oleic acid facilitates penetration into the skin by disrupting the fluidity of the 
stratum corneum. The thermodynamic activity of drug in the formulation is a 
significant driving force for the release and penetration of the drug into skin. The 
results of solubility study have shown table 15. 
 Non–ionic surfactant was selected because they are generally less toxic, 
produce less skin irritation.  The HLB value of the O/W type of microemulsion (9-
12).HLB value of Tween-20(16.7), the required HLB for O/W type of emulsion 
for oleic acid (17) and span-20 HLB value (8.6).The hydrophilic non- ionic 
surfactant, Tween-20 was chosen to formulate these microemulsion systems to 
provide a better permeation profile. The different co-surfactants like butanol, 
ethanol and isopropyle alcohol are used in place of propylene glycol but clarity 
and cumulative percent release was found to be expected with propylene glycol. 
 In microemulsion, the co-surfactant lowers the interfacial tension of the 
surfactant film, resulting in a more flexibility and dynamic layer system. The 
thermodynamic driving force for the release reflects shows the relative activities 
of the drug in different phase. Since drug can be release from the internal phase to 
external phase and then from external phase to the skin, the relative activities may 
monitor the skin permeation flux.  
In addition, the surfactant and co-surfactant may exist in each phase, so 
lornoxicam can partly solubilized in external phase. The depletion of lornoxicam 
may be from the external phase because of the permeation in to the skin can be 
supplemented by the release of lornoxicam from the internal phase. However, the 
oily mixtures of oleic acid, tween-20 and propylene glycol led to increased in drug 
solubility. After extensive screening for physical characteristics and appearance, 
final ratios of surfactants- cosurfactants were decided. The data of selection of 
surfactants and cosurfactants is given in Table 16.   
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In order to identify the optimum ME formulation containing   oleic acid, 
Tween -20, propylene glycol were selected from the trial formulations ratios (1:1, 
2:1) in table17and18. (F1-F10) trial formulations in two ratios (1:1, 2:1) of 
microemulsion formulations were prepared by varying the amount of 
surfactant/co-surfactant.  
 
In 1:1 and 2:1 ratios of trial formulations stable microemulsions were not 
formed. Turbid and conventional emulsions based visual observation. From ten 
trial formulations one (F8) formulation were selected on 2:1 ratio for optimizing 
the formulations. Finally drug, surfactant and co-surfactant is kept constant and oil 
amount was changed. The compositions of microemulsions are given in table 19. 
 
 The microemulsion (ME-1 to ME-5 were subjected to the study of Opticle 
transparency.ME-3formulation were optically clear, transparent and elegant in 
appearance when compared to the other microemulsion formulations Fig 27.  
 
 The pH values of ME-1 to ME-5 (6.12±0.04, 5.75±0.03, 6.42±0.02, 
5.81±0.03, 4.35±0.06) units only. In all cases pH showed the smallest changes. 
The pH value of optimized lornoxicam microemulsion formulation (ME-3) was 
6.42±0.02 (table 32) and is suitable for topical as well as transdermal application 
because the pH of skin in the range 5.5 to 7.0. 
 
 It was clear from the viscosity of microemulsion systems (ME-1 to ME-5) 
that the developed formulations have gradually increased (52.6±0.6cps, 
75.3±0.8cps, 91.4±0.4cps, 103.5±0.5cps, 118.2±0.2cps). All samples exhibited 
Newtonian flow behaviour, as expected from microemulsions. It could be noted that 
the viscosity values tended to increase slightly when the water concentrations 
increased or when the system turned into oil/water type because oil/water 
microemulsions have higher viscosities than those of water/oil systems in table 33.  
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 The Centrifugation stress test of formulations ME-3 shows good 
physical stability and no phase separation when were centrifuged at 2000 rpm for 
60mins Fig 32. 
 
The morphology of MEs was characterized using Transmission Electron 
Microscopy (Fig.33).The TEM image of optimized best formulation showed that 
globules were spherical in shape and had smooth surface. The results TEM further 
indicated the excistance of an isotropic dispersion of spherical droplets, leading to 
the assumption of inverse micelles because of the proporsion of the constituents.  
 
 The particle size distribution of the best microemulsion formulation (ME-
3) ranged from 0.276µm to 1.231 µm with the average droplet size of (ME-3) 
0.78µm. The result shows that the droplet diameter decreases with increasing ratio 
of oil and surfactant: co-surfactant. Due to the small droplet size of (ME-3) 
microemulsion, its surface areas are assumed to be high. Therefore, droplets of 
microemulsion settled down to close contact with the skin providing high 
concentration gradient and improved ornoxicam permeation from formulation 
(ME-3). 
 
 The average droplet size of the best microemulsion formulation (ME-3) 
was determined by Atomic Force Microscopy. The average droplet sizes of  
ME-3 0.88µm and 0.45µm. The droplet size distribution curves of ME-3 were 
presented in Fig: (a.34), (b.35).    
 
The mean percent drug content in microemulsion formulations (ME-1 to 
ME-5) was found to be respectively. (82.42± 0.32%,  93.12± 0.54%,  98.54± 
0.26%, 90.21± 0.46%, 86.34 ±0.28%). ME-3 was exhibited 98.54± 0.26% higher 
drug content then other formulations Table 35.  
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 The permeation capability of the microemulsion formulations were evaluated 
by conducting the in-vitro skin permeation experiments. ME (1-5) lornoxicam 
microemulsions were studied for in vitro skin permeation through excised goat 
skin. The amount of lornoxicam permeated through excised goat skin over 24-
hour period was plotted against the function of time (Fig 38), the permeation 
fluxes (µg/cm2/hour) for all these microemulsions through the goat skin were 
determined. The determined permeation fluxes are given in Table36. Among all 
formulations, the highest permeation flux of µg/cm2/hour was observed in case of 
formulation ME-3.  
 
 The in vitro lornoxicam permeation data from microemulsions containing 
lornoxicam through excised goat skin were evaluated kinetically by various 
mathematical models like zero-order, first-order, Higuchi, and Korsmeyer-Peppas 
model .The results of the curve fitting into these above-mentioned Mathematical 
models indicate the in vitro Lornoxiam permeation behavior of Lornoxicam  
microemulsions (ME-1 to ME-5) (Table 37). 
 
 When respective correlation coefficients were compared, ME-1, ME-2, 
ME-3, ME-4 and ME-5. ME-3 followed the zero-order release (r2 = 0.982) over a 
period of 24 hours. Again, the Korsmeyer-Peppas model was employed in the in 
vitro lornoxicam permeation behavior analysis of these formulations to find out 
permeation mechanisms: Fickian (nonsteady) diffusional release when n ≤ 0.5, 
case-II transport (zero-order) when n ≥ 1, and non-Fickian, “anomalous” release 
when the value of n is in between 0.5 and 1.   
 
The determined values of diffusion exponent (n=0.1) in (Table37). ME-3 
indicating that the drug permeation from lornoxicam microemulsion followed the 
non-Fickian, “anomalous” mechanism. 
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 Stability of the prepared microemulsion formulations was assessed using 
accelearated temperature study. The  drug content, pH, viscosity of the best 
formulation ME-3 were subjected to stability studies at 40°C/75% RH up to 3 
months. the results are summarized in table 44. ME-3 Sample showed excellent 
results in these studies. Drug degradation was found to be in the range (98.23%, 
98.01%, and 97.36%) after three months. Viscosity values after three months 
compared to the initial viscosity were in the range 0-1cps, while pH changed 6-5 
units only. In all cases, ME-3 showed the smallest changes in these parameters. 
Overall results from the stability studies indicated that the microemulsions were 
chemically stable for three months.  
 
 Transdermal treatment of the rats with lornoxicam significantly inhibits 
the oedema size induced by carrageen injection into the sub-plantar area of the 
right hind paw for each rat. It is observed from figures (61) and (62) that the 
groups that treated with lornoxicam microemulsion formulation exhibit a 
maximum percent oedema inhibition after 1hr, 2hr, 3hr, respectively, which is 
lower than that of control group (Fig 63).  
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CONCLUSION 
 The study demonstrates that the microemulsion formulation can be 
employed to improve the solubility of the poorly water soluble drug. Oleic acid 
has consumed maximum amount of lornoxicam and thus chosen as a vehicle for 
microemulsion oil phase. Tween-20 and propylene glycol at appropriate ratios 
were selected as an ideal surfactant and co-surfactant. 
 Lornoxicam Microemulsion was formulated as controlled release dosage 
form for the period of 24hrs and also reduced the side effects produced by oral 
conventional doses. 
 Characterization of the selected ME-3 formulation containing oleic acid 
(6%), Tween-20/propylene glycol (30%), showed their stability after exposure to a 
centrifuge stress test. Their viscosity and droplet particle size showed their 
suitability for transdermal application and their pH values are within the 
physiological range. 
 Drug content of the formulation revealed the % of the 
formulation98.54±0.26%.   
 This study highlighted the efficacy of lornoxicam ME-3 for enhanced in 
vitro transdermal permeation through goat skin. The skin permeation of the ME-3 
formulation follows zero order kinetics and fit for the korsemeyer-peppas model 
and follows non-fickian (anomalous).  
 From the obtained results in this study, we can conclude that: Group: 1 
(animal groups treated with lornoxicam microemulsion) and Group 2: (animal 
groups treated with control drug).lornoxicam microemulsion (ME-3) produced 
maximum % oedema inhibition after 1hr, 2hr, 3hr respectively, and then 
continued significantly for 3hrs than these  control group.   
BIBLIOGRAPHY 
 
 143 
 
BIBLIOGRAPHY 
1. Chien YW. Transdermal Drug Delivery and Delivery Systems, in: 
Y.W.Chien, Novel Drug Delivery Systems, 2nd ed, Chapter 7, Marcel Dekker, 
New York, 1992: 301-380. 
2. Vyas SP and Khar RK. Targetted and Controlled Drug Delivery Novel 
Carrier System 1st ed., CBS Publishers and Distributors, New Delhi, 
2002:411-447. 
3. Hadgraft J, Guy R. In; Transdermal Drug Delivery, Marcel Dekker, Inc., New 
York and Basel,35,296. 
4. Prausnitz MR, Mitragotri S, Langer R. Current Status and Futyre Potential of 
Transdermal Drug Delivery. Nature Reviews, Drug Discovery, 2004; (3):115-
124. 
5. Elias PM, Brown BE, Fritsch P, Goerke J, Gray GM, White RJ. J. Invest 
Dermatol., 1979; 73: 339-48. 
6. Govil SK, In; Tyle, P., Eds., Drug Delivery: Fundamentals and Application, 
Marcel Dekker, Inc., New York, 1998: 385-406  
7. Jain NK. Contolled and Novel Drug Delivery, Cbs Publisher and Distributor, 
1st ed,100 
8. Jayaswal SB, Sood R, the Eastern Pharmacist, 1987; 30(357): 47-50. 
9. Hoar TP, Schulman JH, Transparent Water- In-Oil Dispersions, The 
Oleopathic Hydro-Micelle, Nature, 1943: 152; 102-103. 
10. Schulman, J.H, Stoeckenius, W Prince, L.M, Mechanism Of Formation and 
Structure Of Microemulsions By Electron Microscopy, J. Phys. Chem,  1959: 
63,1677-1680. 
11. Vyas SP, Khar RK. Submicron Emulsions in Targeted and Controlled Drug 
Delivery, Novel Carrier System; Cbs Publishers and Distributors, New Delhi, 
2002:(282-302). 
BIBLIOGRAPHY 
 
 144 
 
12. Jadhav KR. et al., Applications Of Microemulsion Based Drug Delivery 
System. Curr Drug Deliv, 2006; 3(3):267-73.  
 
13. Cordero J, Alarcon L, Escribano E, Obach R, Domenech J. A Comparative 
Study Of The Transdermal Penetration Of A Series Of Nonsteroidal Anti-
Inflammatory Drugs, J. Pharm. Sci, 1997, 86:503–508. 
14. Prince L M, Microemulsions. In: Lissant KJ (Ed), Emulsions And Emulsion 
Technology,New York : Marcel Dekker; 1974: 125-178.  
15. Delgado-Charro MB, Iglesias-Vilas G, Blanco-Mendez J, Lopez QM, Marty 
Jp, Guy RH. Delivery Of A Hydrophilic Solute Through The Skin From 
Novel  Microemulsion Systems. Eur J Pharm Biopharm 1997; 43: 37-42. 
16. Celebi N, Kıslal O, Tarımcı N. The Effect of Β- Cyclodextrin And 
Penetration Additives On The Release Of Naproxen From Ointment Bases. 
Pharmazie 1993; 48: 914-9179, Gasco M R, Gallarate M, Trotta M, 
Bauchiero L, Gremmo E, Chiappero O, J. Pharm. Biomed,1989; 7: 433. 
17. Holmberg, K., Handbook of Applied Surface and Colloid Chemistry. 2002: 
Chichester, New York, Wiley. 
18. Giustini MS, Murgia G, Palazzo. Does The Schulman's Titration Of 
Microemulsions Really Provide Meaningful Parameters? Langmuir, 2004; 
20(18):7381-4. 
19. Giustini, M., et al., Microstructure and Dynamics of The Water-In-Oil 
Ctab/Npentanol/N-Hexane/Water Microemulsion: A Spectroscopic And 
Conductivity  Study, Journal Of Physical Chemistry, 1996; 100(8): 3190-98. 
20. Lawrence MJ, Rees GD. Microemulsion-Based Media As Novel Drug 
Delivery Systems, Adv Drug Deliv Rev, 2000; 45(1): 89-121. 
21. http/www.wikipedia.org/Rheumatoid arthritis 
22. Googman and Gilman’s The Pharmacological Basis of Therapeutics, 11th 
Edition, 2005. P. 1415, Unit II, “Disease Of Organ System” 1304-1309 
BIBLIOGRAPHY 
 
 145 
 
23. Rang and Dale’s pharmacology 6th edition, Anti-inflammatory activity of 
NSAIDs p. 215. 
24. Tripathi Kd, Essentials Of Medical Pharmacology. 5th Ed. Published By 
Jaypee Brother’s Medical Publisher’s Pvt. Ltd., New Delhi: 2003:167-184.  
25. http/www.wikipedia.org/Inflammation 
26. Jadupatimalakar, Suma OS, Amit KN. Development and Evaluation 
Ofmicroemulsions For Transdermal Delivery Of Insulin,Research 
Article,201:1-7. 
27. Bhavika H. Zala,  Radhik BP, Manali DP,  Ramkishan. Formulation And 
Development of Microemulsion Drug Delivery System Of Acyclovir For 
Enhancement of Permeability, Journal of Pharmacy Research, 2011:4(3),930-
933. 
28. Xiaohui D, Xue K, and Zhenggen L. The Microstructure Characterization Of 
Meloxicam Microemulsion And Its Influence On The Solubilization Capacity, 
Research Article, 2011; 37(8): 894-900. 
29. Ying C, Lingzhi L, Jun G, Ting Z And LZ, Investigation Of Microemulsion 
System For Transdermal Delivery of Ligustrazine Phosphate, October, 2011, 
African Journal of Pharmacy And Pharmacology.  Vol. 5(14); 1674-81,  
30. Manish K Singh, Vikas Chandel, Vandana Gupta and Suman Ramteke 
Formulation Development and Characterization Of Microemulsion For 
Topical Delivery Of Glipizide, Scholars Research Library, Der Pharmacia 
Lettre, 201: 2(3), 33-42 
31. Brajesh Kumar, Sanjay Kumar Jain, Sunil Kumar Prajapati, Alok Mahor  
Development and Characterization Of Transdermal Microemulsion Gel  
For  an Antiviral Drug, International Journal Of Pharmaceutical Sceiences 
and Research, 2010;1(6): 58-74. 
32. Kalra R, Mulik RSA, Badgujar L, Paradkar AR. Development and 
Characterization of Microemulsion Formulations For Transdermal Delivery 
BIBLIOGRAPHY 
 
 146 
 
Of Aceclofenac : A Research,  International Journal Of Drug Formulation & 
Research, Aug-Sep. 2010; 1(1):359-386. 
33. Anjali C H, Madhusmita Dash, N Chandrasekaran, Amitava Mukherjeeanti 
Bacterial Activity Of Sunflower Oil Microemulsion, International Journal Of 
Pharmacy And Pharmaceutical Sciences.2010; 2:123-128. 
34. Mrunali RP, Rashmin BP, Jolly RP, Kashyap KB.  Investigating The Effect of 
Vehicle On in vitro Skin Permeation Of Ketoconazole Applied In O/W 
Microemulsions,  Acta Pharmaceutica Sciencia,  2010; 52: 65-77. 
35. Fathy I, Abd-Allah, Hamdy MD, Ahmed MS, Preparation, Characterization, 
And Stability Studies of Piroxicam Loaded Microemulsions In Topical 
Formulations, Original Article,  Drug Discoveries & Therapeutics, 2010; 
4(4):267-275. 
36. Tian QP, Li P And Xie KC. Investigation Of Microemulsion System For 
Transdermal Drug Delivery Of Amphotericin B, Chem. Res. Chinese 
Universities 2009; 25(1): 86-94. 
37. Rohit RS, Chandrakant M, Kiran AW. Fluconazole Topical Microemulsion: 
Preparation and Evaluation Research J. Pharm. And Tech.2 (2): April.-
June.2009: 352-358 
38. Zhai , Guo C, Yu A, Gao Y, Cao F, Microemulsion-Based Hydrogel 
Formulation Of Penciclovir For Topical Delivery. Int J Pharm. 2009; 378(1-
2):152-8. 
39. Arun K. Dhamankar, Jagdish V Manwar, And Dipak D Kumbhar, The Novel 
Formulation Design of O/W Microemulsion of Ketoprofen For Improving 
Transdermal Absorption,International Journal of Pharmtech Research, Oct-
Dec 2009; 1(4):1449-57. 
40. Mostafa DM. Investigation of A Transdermal Microemulsion Delivery 
System For Fluoxetine Hydrochloride, Asian Journal Of Pharmaceutical 
Sciences, 2008; 3 (2): 68-79. 
BIBLIOGRAPHY 
 
 147 
 
41. Gamal M. Self-Microemulsifying And Microemulsion Systems For 
Transdermal Delivery Of Indomethacin: Effect Of Phase Transition. Colloids 
Surf B Biointerfaces. 2010 Feb 1;75(2): 595-600. 
42. Ambade KW, Jadhav SL, Gambhire MN, Kurmi SD, Kadam VJ, Jadhav KR. 
Formulation And Evaluation Of Flurbiprofen Microemulsion,  Current Drug 
Delivery 2008; 5(1):32-41. 
43. Gamal M Maghraby Gm. Transdermal Delivery of Hydrocortisone From 
Eucalyptus Oil Microemulsion: Effects Of Cosurfactants. Int J Pharm. 2008 
May 1: 355(1-2):285-92. 
44. Ke-Shu Y, Ting-Xu Y, Hong G, Ji-Zhong L. Evaluation of Transdermal 
Permeability of Pentoxifylline Gel: in vitro Skin Permeation and in vivo 
Microdialysis Using Wistar Rats, Orignal Article Drug Discov Ther, 2007; 
1(1):78-83 
45. Anna K, Nissim G.Microemulsion As Transdermal Drug Delivery Vehicles. 
Advance In Colloidal And Interface Science 2006: 123-6, 369-85. 
46. Huabing C, Xueling C, Danrong D, Jin L, Huibi X, Xiangliang Y. 
Microemulsion-Based Hydrogel Formulation Of Ibuprofen For Topical 
Delivery. Int J Pharm, 2006; 315: 52-58. 
47. Gupta S, Moulik SP, Lala S, Basu MK, Sanyal SK And Datta S. Designing 
and Testing Of An Effective Oil-In-Water Microemulsion Drug Delivery 
System For Invitro Application. Drug Delivery.  2005; 12(5):267-273. 
48. Haubing C, Xueling C, Weng T, Xiaozhi Z, Zhonghong G, Yajing Y, Huibi 
X. A Syudy Of Microemulsion Systems For Transdermal Delivery Of 
Triptolide. J Control Release. 2004; 98:427-436. 
49. Fang, Yann LL, Chia CC, Chia H ,Hung T, Lipid Nano/Submicron Emulsions 
As Vehicles For Topical Flubriprofen Delivery. Drug Delivery                       
2004; 11:97-105. 
BIBLIOGRAPHY 
 
 148 
 
50.Baroli B, López-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-
     Mendez J. Microemulsions For Topical Delivery Of 8-Methoxsale,J 
     Control Release. 2000Oct; 3,69(1):209-18. 
51.Mohammed C and Manoj V, Aerosol-Ot Microemulsions As Transdermal 
     Carriers of Tetracaine Hydrochloride Drug Development And       Industrial 
     Pharmacy, Research Paper ,2000; 26(5):507–512. 
52.Shaul M, Muhamad A, Joseph F P, Simon B, Ex-Vivo Permeation Study of 
      Indomethacin From A Submicron Emulsion Through Albino Rabbit Cornea. J 
     Control Release,1997; 44:55-64. 
53..Kavitha K, Mangesh R. Design And Evaluation of Transdermal Films 
    Of Lornoxicam International Journal Of Pharma And Bio Sciences, Apr-Jun 
    2011; 2(2):54-62. 
54.Parikh BA, Najmuddin M, Kulkarni U And Hariprasanna RC. Preparation And 
    Evaluation of Sustained Release Matrix Tablets Of  Lornoxicam Using 
    Tamarind Seed Polysaccharide, International Research  Journal Of Pharmacy, 
    2011: 2(4):130-133. 
55.Phani KGK, Gangarao B,  Lova RNS, Kotha. Preparation And Evaluation Of 
    Sustained Release Matrix Tablets Of Lornoxicam Using Tamarind Seed 
    Polysaccharide, International Journal Of Pharma Research And Development, 
    2011;2(12): 89-98. 
56. Syed NU, Anup KR, Martand K, Vinod KSM. Formulation and Evaluation Of 
      Sustained Release Matrix Tablets of  Lornoxicam,  International Journal Of 
      Drug Development & Research, Jan-Mar 2011;3(1): 31-65. 
57.Ganesh NS, Deecaraman. Chronomodulated Drug Delivery System Of 
      Lornoxicam Using Natural Polymers  Journal Of Pharmacy Research     
      2011:4(3);825-828. 
BIBLIOGRAPHY 
 
 149 
 
58.Sandeep KD, Shashidhar RK, Amit KT And Suddhasattya Dey, Design And 
     Evaluation of Buccal Patches of Lornoxicam, International Journal Of Pharma 
    And Bio Sciences, Oct-Dec2010:1(4). 
59. Bhavsar KC, Gaikwad PD, Bankar VH And Pawar SP. Development And 
      Validation Of UV-Spectrophotometric Method For Simultaneous Estimation 
     Of Paracetamol and Lornoxicam In Bulk And Tablet Dosage Form 
     International Journal Of Pharmacy&Technology,  2010; 2(2):429-439. 
60.Lakshmi S, Lakshmi KS And Tintu T. Simultaneous Spectrophotometric 
     Estimation Of Paracetamol And Lornoxicam In Tablet Dosage Form, 
     International Journal Of Pharmacy And Pharmaceutical Sciences, 2010; 
     2(4):166-168. 
61.Rajesh SJ, Swadesh N, Sabita A, Vikas D,  Taste Masking Of Lornoxicam By 
    Polymer Carrier System And Formulation Of Oral Disintegrating Tablets, 
    International Journal Of Drug Delivery 2009: 27-31. 
62. Berry H, Bird H A, Black C, A Double Blind, Multicone, Placebo Controlled 
     Trial of Lornoxicam In Patients With Osteoarthritis Of The Hip And Knee, 
     The Eular Journal, Feb 1992; 51(2):238-242.  
63.Fathy IA, Hamdy M, Dawaba, Ahmed M, Evaluation Of The 
     Antiinflammatory and Analgesic Effects Of Piroxicam loaded 
     Microemulsion In Topical Formulations, International Journal Of Pharmacy 
     and Pharmaceutical Sciences.2011; 3(2):66-70. 
64.Nahla Barakat, Ehab Fouad, Azza Elmedany, Enhancement of  skin 
     permeation and anti-inflammatory effect of indomethacin using 
     microemulsion, research article. 2011: 5(3);141-149.   
65.Ashutosh M, Ravichandran V, Prateek KJ, Vinod Kd, Ram Ka. Synthesis, 
     haracterization and Pharmacological Evaluation of Amide Prodrug of 
     Flurbiprofen, J.Braz.Chem.Soc. 2008; 19(1):89–100. 
BIBLIOGRAPHY 
 
 150 
 
66.Buritova J, Besson J M, Dose Related Anti-Inflammatory And Analgesic 
     Effects Of Lornoxicam: A Spinal C-Fos Protein Study In The Rat, 
     Inflammation Research.1998; 47: 18-25. 
67. http://www.chemblink.com 
68.Ravic M, Johnston A, Turner P. Clinical Pharmacological Studies Of Some 
     Possible Interactions Of Lornoxicam With Other Drugs Postgrad Med J 
     1990; 66(4): 30-34. 
69.Hitzenberger G, Welte SR, Takacs F, Rosenow D. Pharmacokinetics Of 
     Lornoxicam In Man. Postgrad Med J 1990; 66(4):22-6. 
70.Julia A, Balfour AF, Barradell LB, Lornoxicam: A Review of Its 
     Pharmacology And Therapeutic Potential In The Management of Painful and 
     Inflammatory Conditions. Drugs 1996; 51(4):639-57. 
71.Berg J, Christoph T, Fellier H. The Analgesic NSAID Lornoxicam Inhibits      
     Cox-1/Cox-2.The Formation Of II-6 In Vitro, Naunyn-Schmied  Arch 
     Pharmacol 1998; 358(2):716. 
72.Welte SR, Rabbeseda X. Lornoxicam, A  New Potent Nsaid With 
     Improved Tolerability Profile, Drugs Of Today  2000; 36(1):55-76. 
73.Smolinske SC. Handbook Of Food, Drug, And Cosmetic Excipients. Boca 
     Raton, Fl: CRC Press, 1992: 295-301. 
74.Francoeur M I , Golden G M, Potts R O, Oleic Acid: Its Effects On Stratum 
     Corneum In Relation to (Trans) Dermal Drug Delivery, Pharm Res 1990; 
     7: 621-627. 
75.Murakami T, Yoshioka M, Yumoto R. Topical delivery of keloid therapeutic 
     drug, tranilast, by combined use of oleic acid and propylene glycol as a        
     penetration enhancer: evaluation by skin microdialysis in rats. J Pharm 
     Pharmacol 1998: 49–54. 
 
 
BIBLIOGRAPHY 
 
 151 
 
     76. Khossravi M, Kao Y-H, Mrsny RJ, Sweeney TD. Analysis methods of 
          polysorbate 20: a new method to assess the stability of polysorbate 20             
          and established methods that may overlook degraded polysorbate 20. 
77.Arulanantham K, Genel M. Central nervous system toxicity associated  with 
     ingestion of propylene glycol, J Pediatr 1978; 93:515–516. 
      78.E.A.Rawlins, Bently’s Text book of pharmaceutics, Bailliere Tindall, London, 
           8th ed, 663. 
      79.Martin’s physical pharmacy pharmaceutical sciences.5th ed.India: Wolters       
           Kluwer; 2007:448. 
80.Bourne DW, Pharmacokinetics, In: Banker GS, Rhodes CT,“Modern 
     Pharmaceutics”, 4th ed, New York, NY: Marcel Dekker Inc; 2002:67-92 
 81.Higuchi T. “Theoretical Analysis of Rate of Release of Solid Drugs Dispersed 
      in Solid Matrices”, J Pharm Sci (52)1963:1145-49. 
 82.Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of 
      Solute Release from Porous Hydrophilic Polymers”. Int J Pharm (15),   
     1983:25-35.ed, 431, 444-448. 
83. Manavalan R, Ramasamy C, Physical pharmaceutics, vignesh publisher, 
       Chennai, 321, 322,334-336. 
84.Alfred martin, Physical  pharmacy, B.I. waverly pri. Lit, New Delhi, 4th ed, 
     431, 444-448. 
85. David J. Mazzo, International stability testing, interpharm press,1-13. 
86. http://www.phamacycode.com 
87. http://www.slideworld.com/rhumatoid arthritis 
88. www.scholars research library.com 
89. www.sciencedirct.com 
 
BIBLIOGRAPHY 
 
 152 
 
90. www.rjptonline.org 
91. www.pubmed.com 
92. www.sphinsai.com 
93. Indian Pharmacopoeia (I.P.), vol. II, 1996:443.  
94. Brahmankar,D M B.Jaiswal “Biopharmaceutics and pharmacokinetics a 
Treatise”, Vallabh prakasham, Delhi 1st edition, 2002: 347-352. 
95. Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA and Ekbom A. 
Nabumetone: Therapeutic Use and Safety Profile in the Management of 
Osteoarthritis's and Rheumatoid Arthritis Drugs. 2004; 64(20): 2315‐43. 
 
 
